<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link href="https://feeds.simplecast.com/_70AInrh" rel="self" title="MP3 Audio" type="application/atom+xml"/>
    <atom:link href="https://simplecast.superfeedr.com" rel="hub" xmlns="http://www.w3.org/2005/Atom"/>
    <generator>https://simplecast.com</generator>
    <title>Inside Biotech</title>
    <description>Inside Biotech is an exciting podcast from BCLA, which focuses on the science behind SoCal’s most innovative new biotech companies. This monthly podcast, hosted by Riley Conover Elmer and Karishma Chhugani, two Ph.D. Candidates at USC, and is the perfect way for anyone interested in LA’s biotech community to stay informed about current progress and developments. Episodes feature conversations with scientists, entrepreneurs, investors, and more about the cutting-edge science that goes on inside their companies to offer listeners diverse perspectives from experts across niches and levels in the biotech space. On Inside Biotech, science story-telling meets big business, touching on a range of themes from across the world of southern California’s biotechnology industry.</description>
    <copyright>2025 Inside Biotech</copyright>
    <language>en</language>
    <pubDate>Mon, 2 Mar 2026 17:00:00 +0000</pubDate>
    <lastBuildDate>Thu, 19 Mar 2026 10:06:36 +0000</lastBuildDate>
    <image>
      <link>https://inside-biotech.simplecast.com</link>
      <title>Inside Biotech</title>
      <url>https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/b343ce7a-5297-40d2-b9e2-40ac6b496429/3000x3000/biotech-20riley-20karishma.jpg?aid=rss_feed</url>
    </image>
    <link>https://inside-biotech.simplecast.com</link>
    <itunes:type>episodic</itunes:type>
    <itunes:summary>Inside Biotech is an exciting podcast from BCLA, which focuses on the science behind SoCal’s most innovative new biotech companies. This monthly podcast, hosted by Riley Conover Elmer and Karishma Chhugani, two Ph.D. Candidates at USC, and is the perfect way for anyone interested in LA’s biotech community to stay informed about current progress and developments. Episodes feature conversations with scientists, entrepreneurs, investors, and more about the cutting-edge science that goes on inside their companies to offer listeners diverse perspectives from experts across niches and levels in the biotech space. On Inside Biotech, science story-telling meets big business, touching on a range of themes from across the world of southern California’s biotechnology industry.</itunes:summary>
    <itunes:author>Daniel Arce, Bryan Jimenez, Stephanie Wu, Danielle Luu, Deneé Easy, Kat Merkling, Riley Elmer, Karishma Chhugani</itunes:author>
    <itunes:explicit>false</itunes:explicit>
    <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/b343ce7a-5297-40d2-b9e2-40ac6b496429/3000x3000/biotech-20riley-20karishma.jpg?aid=rss_feed"/>
    <itunes:new-feed-url>https://feeds.simplecast.com/_70AInrh</itunes:new-feed-url>
    <itunes:keywords>biotech, science, bcla, california, la, los angeles, science-storytelling, 971893</itunes:keywords>
    <itunes:owner>
      <itunes:name>Biotech Connection Los Angeles</itunes:name>
      <itunes:email>team@bc-la.org</itunes:email>
    </itunes:owner>
    <itunes:category text="Science"/>
    <itunes:category text="Business"/>
    <itunes:category text="Education"/>
    <item>
      <guid isPermaLink="false">14bdce41-5675-4a13-9fec-880a4b8340bf</guid>
      <title>Where Life Science Meets Litigation</title>
      <description><![CDATA[<p>In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 2 Mar 2026 17:00:00 +0000</pubDate>
      <author>team@bc-la.org (Daniel Graves, Daniel Arce, Stephanie Wu, Danielle Luu, Bryan Jimenez, Riley Elmer, Karishma Chhugani)</author>
      <link>https://inside-biotech.simplecast.com/episodes/where-life-science-meets-litigation-D19ksB9b-JFyo57sT</link>
      <content:encoded><![CDATA[<p>In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="35467223" type="audio/mpeg" url="https://cdn.simplecast.com/media/audio/transcoded/68c872f7-b917-49d4-bc0c-9e247eb04831/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/audio/group/92eb1bbc-c3b2-4ef9-95cb-d3de7f1b3e5e/group-item/7f83d862-d813-441c-95e6-56dab49cb153/128_default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Where Life Science Meets Litigation</itunes:title>
      <itunes:author>Daniel Graves, Daniel Arce, Stephanie Wu, Danielle Luu, Bryan Jimenez, Riley Elmer, Karishma Chhugani</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/bfe573a6-baf1-4185-99ab-adb96bc72b06/3000x3000/img2512.jpg?aid=rss_feed"/>
      <itunes:duration>00:36:56</itunes:duration>
      <itunes:summary>In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem.</itunes:summary>
      <itunes:subtitle>In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem.</itunes:subtitle>
      <itunes:keywords>development, biotech connection los angeles, innovation, biotechnology, inside biotech, biotech, law, patent law, career transition, mintz</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>39</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">41127fc4-437a-46de-ba37-047c9afabf75</guid>
      <title>5 Key Findings to Becoming a Great Scientific Mentor with Riley Elmer</title>
      <description><![CDATA[<p>What actually makes a good mentor, and how do you find one who’s right for you? In this episode of Inside Biotech, new host Riley explores how mentorship shapes scientific careers, sharing five key principles for building strong mentor–mentee relationships. Drawing from personal experience, the conversation highlights aligning values, looking beyond expertise, and embracing productive tension to support growth in science. Perfect for graduate students and early-career researchers navigating advisor relationships, lab culture, and long-term career development in academia or industry.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Thu, 29 Jan 2026 19:30:00 +0000</pubDate>
      <author>team@bc-la.org (Stephanie Wu, Bryan Jimenez, Daniel Arce, Danielle Luu, Riley Elmer, Karishma Chhugani, Katherine Merkling, Deneé Easy)</author>
      <link>https://inside-biotech.simplecast.com/episodes/5-key-findings-to-becoming-a-great-scientific-mentor-with-riley-elmer-8ujIAbtf</link>
      <content:encoded><![CDATA[<p>What actually makes a good mentor, and how do you find one who’s right for you? In this episode of Inside Biotech, new host Riley explores how mentorship shapes scientific careers, sharing five key principles for building strong mentor–mentee relationships. Drawing from personal experience, the conversation highlights aligning values, looking beyond expertise, and embracing productive tension to support growth in science. Perfect for graduate students and early-career researchers navigating advisor relationships, lab culture, and long-term career development in academia or industry.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="34818968" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/852e2988-84e7-4eb7-b290-bcb82af2f4d1/audio/ee10d9ea-ad0f-41e9-954a-729b383d053a/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>5 Key Findings to Becoming a Great Scientific Mentor with Riley Elmer</itunes:title>
      <itunes:author>Stephanie Wu, Bryan Jimenez, Daniel Arce, Danielle Luu, Riley Elmer, Karishma Chhugani, Katherine Merkling, Deneé Easy</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/aba63266-1677-41c2-9d3f-3186de8b8c78/3000x3000/square.jpg?aid=rss_feed"/>
      <itunes:duration>00:36:16</itunes:duration>
      <itunes:summary>What actually makes a good mentor, and how do you find one who’s right for you? In this episode of Inside Biotech, new host Riley explores how mentorship shapes scientific careers, sharing five key principles for building strong mentor–mentee relationships. Drawing from personal experience, the conversation highlights aligning values, looking beyond expertise, and embracing productive tension to support growth in science. Perfect for graduate students and early-career researchers navigating advisor relationships, lab culture, and long-term career development in academia or industry.</itunes:summary>
      <itunes:subtitle>What actually makes a good mentor, and how do you find one who’s right for you? In this episode of Inside Biotech, new host Riley explores how mentorship shapes scientific careers, sharing five key principles for building strong mentor–mentee relationships. Drawing from personal experience, the conversation highlights aligning values, looking beyond expertise, and embracing productive tension to support growth in science. Perfect for graduate students and early-career researchers navigating advisor relationships, lab culture, and long-term career development in academia or industry.</itunes:subtitle>
      <itunes:keywords>values, roles, mentorship, mentor, podcast, experience, leadership, phd, mentee, growth, student, graduate student, expectations, scientist</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>38</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f0945673-0869-4a9f-95fd-0496ed3e715d</guid>
      <title>From One Voice to Many: Gabriella Rubert, Riley Conover Elmer &amp; Karishma Chhugani</title>
      <description><![CDATA[<p>In this episode, Gabriella Rubert joins the Biotech Connection Los Angeles team for a thoughtful conversation reflecting on her journey as a host of the Inside Biotech podcast. Together, they explore the challenges and rewards of science communication, the responsibility of making complex scientific topics accessible, and the impact storytelling has in connecting the biotech community with the public. The discussion highlights the importance of networking, mentorship, and embracing non-linear career paths in science, while also touching on personal growth, confidence, and the value of asking for help along the way. As the episode marks a meaningful transition, Gabriella reflects on her experiences behind the mic and passes the torch to the next generation of Inside Biotech hosts.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 29 Dec 2025 20:00:00 +0000</pubDate>
      <author>team@bc-la.org (Karishma Chhugani, Riley Elmer, Deneé Easy, Bryan Jimenez, Stephanie Wu, Amaryllis Tsiknia, Danielle Luu, Daniel Arce, Daniel Graves, Gabriella Rubert, Serena Gao, Katherine Merkling)</author>
      <link>https://inside-biotech.simplecast.com/episodes/from-one-voice-to-many-gabriella-ruberts-riley-conover-elmer-karishma-chhugani-WYe_82iO</link>
      <content:encoded><![CDATA[<p>In this episode, Gabriella Rubert joins the Biotech Connection Los Angeles team for a thoughtful conversation reflecting on her journey as a host of the Inside Biotech podcast. Together, they explore the challenges and rewards of science communication, the responsibility of making complex scientific topics accessible, and the impact storytelling has in connecting the biotech community with the public. The discussion highlights the importance of networking, mentorship, and embracing non-linear career paths in science, while also touching on personal growth, confidence, and the value of asking for help along the way. As the episode marks a meaningful transition, Gabriella reflects on her experiences behind the mic and passes the torch to the next generation of Inside Biotech hosts.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="29752467" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/ea4518af-095a-4d32-b9c0-9ea3ec03fb14/audio/df4ed5cf-9b9a-4cfc-bf4b-8800f4a188c0/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>From One Voice to Many: Gabriella Rubert, Riley Conover Elmer &amp; Karishma Chhugani</itunes:title>
      <itunes:author>Karishma Chhugani, Riley Elmer, Deneé Easy, Bryan Jimenez, Stephanie Wu, Amaryllis Tsiknia, Danielle Luu, Daniel Arce, Daniel Graves, Gabriella Rubert, Serena Gao, Katherine Merkling</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/42421756-f3a8-45c0-8f93-0eec7c8e5cf2/3000x3000/cohost-20-20-instagram-20post-20-45-20-3.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:59</itunes:duration>
      <itunes:summary>In this episode, Gabriella Rubert joins the Biotech Connection Los Angeles team for a thoughtful conversation reflecting on her journey as a host of the Inside Biotech podcast. Together, they explore the challenges and rewards of science communication, the responsibility of making complex scientific topics accessible, and the impact storytelling has in connecting the biotech community with the public. The discussion highlights the importance of networking, mentorship, and embracing non-linear career paths in science, while also touching on personal growth, confidence, and the value of asking for help along the way. As the episode marks a meaningful transition, Gabriella reflects on her experiences behind the mic and passes the torch to the next generation of Inside Biotech hosts. </itunes:summary>
      <itunes:subtitle>In this episode, Gabriella Rubert joins the Biotech Connection Los Angeles team for a thoughtful conversation reflecting on her journey as a host of the Inside Biotech podcast. Together, they explore the challenges and rewards of science communication, the responsibility of making complex scientific topics accessible, and the impact storytelling has in connecting the biotech community with the public. The discussion highlights the importance of networking, mentorship, and embracing non-linear career paths in science, while also touching on personal growth, confidence, and the value of asking for help along the way. As the episode marks a meaningful transition, Gabriella reflects on her experiences behind the mic and passes the torch to the next generation of Inside Biotech hosts. </itunes:subtitle>
      <itunes:keywords>pharmaceutical science, neuroscience, inside biotech, podcasts, phd, career transition, cohost</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>37</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">84eb0577-df8b-4431-b6ad-f0a96a017f63</guid>
      <title>Shaping Tomorrow&apos;s Researchers with Dr. Reginald Hill, Founder of Lab Lift-off</title>
      <description><![CDATA[<p>What if we’ve been focusing on the wrong cells in cancer? In this episode, Dr. Reginald Hill explains how fibroblasts, inflammation, and tissue stiffness shape tumor behavior and chemoresistance—and how mouse models, organoids, and microfluidic devices can turn those insights into better diagnostics. We dig into his path from a Cell cover story to a patent on an exosome-based cancer detection platform, his work lobbying Congress for pancreatic cancer research, and his aviation-inspired approach to lab management and science career coaching. Perfect for anyone interested in cancer biology, translational tech, or building a scientific career beyond the “traditional” path.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Fri, 21 Nov 2025 17:00:00 +0000</pubDate>
      <author>team@bc-la.org (Amaryllis Tsiknia, Daniel Graves, Kat Merkling, Daniel Arce, Stephanie Wu, Serena Gao, Bryan Jimenez, Gabriella Rubert, Danielle Luu)</author>
      <link>https://inside-biotech.simplecast.com/episodes/shaping-tomorrows-researchers-with-reginald-hill-founder-of-lab-lift-off-KQPt6hng</link>
      <content:encoded><![CDATA[<p>What if we’ve been focusing on the wrong cells in cancer? In this episode, Dr. Reginald Hill explains how fibroblasts, inflammation, and tissue stiffness shape tumor behavior and chemoresistance—and how mouse models, organoids, and microfluidic devices can turn those insights into better diagnostics. We dig into his path from a Cell cover story to a patent on an exosome-based cancer detection platform, his work lobbying Congress for pancreatic cancer research, and his aviation-inspired approach to lab management and science career coaching. Perfect for anyone interested in cancer biology, translational tech, or building a scientific career beyond the “traditional” path.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="58577022" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/55ac5217-3815-47b4-ae9b-dc4a4b6bbac7/audio/ec1c481b-e71f-4412-8df5-d19ea7c5a87f/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Shaping Tomorrow&apos;s Researchers with Dr. Reginald Hill, Founder of Lab Lift-off</itunes:title>
      <itunes:author>Amaryllis Tsiknia, Daniel Graves, Kat Merkling, Daniel Arce, Stephanie Wu, Serena Gao, Bryan Jimenez, Gabriella Rubert, Danielle Luu</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/2803f7a7-6e1d-4ba5-b319-0d99d9b03e94/3000x3000/reginald-20hill.jpg?aid=rss_feed"/>
      <itunes:duration>01:01:01</itunes:duration>
      <itunes:summary>What if we’ve been focusing on the wrong cells in cancer? In this episode, Dr. Reginald Hill explains how fibroblasts, inflammation, and tissue stiffness shape tumor behavior and chemoresistance—and how mouse models, organoids, and microfluidic devices can turn those insights into better diagnostics. We dig into his path from a Cell cover story to a patent on an exosome-based cancer detection platform, his work lobbying Congress for pancreatic cancer research, and his aviation-inspired approach to lab management and science career coaching. Perfect for anyone interested in cancer biology, translational tech, or building a scientific career beyond the “traditional” path.</itunes:summary>
      <itunes:subtitle>What if we’ve been focusing on the wrong cells in cancer? In this episode, Dr. Reginald Hill explains how fibroblasts, inflammation, and tissue stiffness shape tumor behavior and chemoresistance—and how mouse models, organoids, and microfluidic devices can turn those insights into better diagnostics. We dig into his path from a Cell cover story to a patent on an exosome-based cancer detection platform, his work lobbying Congress for pancreatic cancer research, and his aviation-inspired approach to lab management and science career coaching. Perfect for anyone interested in cancer biology, translational tech, or building a scientific career beyond the “traditional” path.</itunes:subtitle>
      <itunes:keywords>science collaboration, stem education, laboratory, career development, biotech initiatives</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>36</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">83cc57ef-5fcf-4da4-a332-5132dea16b1f</guid>
      <title>The Future of Mental Health Treatment with Shawn Singh, CEO of Vistagen</title>
      <description><![CDATA[<p>CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen’s fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth’s role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development and mental health innovation.</p><p>Learn more about Vistagen: <a href="https://www.vistagen.com/">https://www.vistagen.com/</a><br />Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: <a href="https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals">https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Fri, 10 Oct 2025 16:00:00 +0000</pubDate>
      <author>team@bc-la.org (Bryan Jimenez, Daniel Arce, Katherine Merkling, Amaryllis Tsiknia, Daniel Graves, Gabriella Rubert, Serena Gao, Danielle Luu, Stephanie Wu)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-future-of-mental-health-treatment-with-shawn-singh-ceo-of-vistagen-cTBjJart</link>
      <content:encoded><![CDATA[<p>CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen’s fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth’s role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development and mental health innovation.</p><p>Learn more about Vistagen: <a href="https://www.vistagen.com/">https://www.vistagen.com/</a><br />Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: <a href="https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals">https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="49880963" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/47083178-c5a8-4285-80c3-3daf757f34f7/audio/9f6f8777-bcb8-452d-883b-1db0e2e47b48/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The Future of Mental Health Treatment with Shawn Singh, CEO of Vistagen</itunes:title>
      <itunes:author>Bryan Jimenez, Daniel Arce, Katherine Merkling, Amaryllis Tsiknia, Daniel Graves, Gabriella Rubert, Serena Gao, Danielle Luu, Stephanie Wu</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/bf4fa5b1-eba4-4c49-bec3-553a2090f4da/3000x3000/square-shawn-20singh-vistagen.jpg?aid=rss_feed"/>
      <itunes:duration>00:51:57</itunes:duration>
      <itunes:summary>CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen’s fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth’s role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development, and mental health innovation.

Learn more about Vistagen: https://www.vistagen.com/
Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals</itunes:summary>
      <itunes:subtitle>CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen’s fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth’s role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development, and mental health innovation.

Learn more about Vistagen: https://www.vistagen.com/
Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals</itunes:subtitle>
      <itunes:keywords>medicine, vistagen, world mental health day, science communication, inside biotech, clinical trials, mentalhealth, drug development, intranasal therapeutics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>35</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2136b8b2-b98d-4ac0-a059-b21b6f58680b</guid>
      <title>Revolutionizing Biotechnology with Exozymes: Michael Heltzen, CEO of Exozymes</title>
      <description><![CDATA[<p>Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. </p><p>Make sure to check out eXoZymes' website: <a href="https://exozymes.com/">https://exozymes.com/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 1 Oct 2025 15:50:00 +0000</pubDate>
      <author>team@bc-la.org (Daniel Arce, Danielle Luu, Amaryllis Tsiknia, Stephanie Wu, Bryan Jimenez, Serena Gao, Gabriella Rubert, Katherine Merkling, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen-vbn4hoMN</link>
      <content:encoded><![CDATA[<p>Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. </p><p>Make sure to check out eXoZymes' website: <a href="https://exozymes.com/">https://exozymes.com/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="62833936" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/99277540-cbc8-411e-a19a-a2ababce6f9c/audio/a2293f6e-11e5-42e0-9e31-f905d565b4ad/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Revolutionizing Biotechnology with Exozymes: Michael Heltzen, CEO of Exozymes</itunes:title>
      <itunes:author>Daniel Arce, Danielle Luu, Amaryllis Tsiknia, Stephanie Wu, Bryan Jimenez, Serena Gao, Gabriella Rubert, Katherine Merkling, Daniel Graves</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/4b268d7d-4e09-4922-9829-e45adccf40b8/3000x3000/square-michael-20heltzen.jpg?aid=rss_feed"/>
      <itunes:duration>01:05:27</itunes:duration>
      <itunes:summary>Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is &quot;liberating enzymes from cells&quot; to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech&apos;s funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology&apos;s next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. 

Make sure to check out eXoZymes&apos; website: https://exozymes.com/</itunes:summary>
      <itunes:subtitle>Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is &quot;liberating enzymes from cells&quot; to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech&apos;s funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology&apos;s next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. 

Make sure to check out eXoZymes&apos; website: https://exozymes.com/</itunes:subtitle>
      <itunes:keywords>industrial revolution in biotech, sustainable chemistry, drug discovery, insidebiotech, exozymes, synthetic biology, bcla, ai driven biotech, enzyme scalability</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>34</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">a3dfad52-b6f1-4190-8d3c-862e31ecbddf</guid>
      <title>Diagnosing the Undiagnosed: John Marlow and Pete Kane of Research to the People</title>
      <description><![CDATA[<p>In this episode of Inside Biotech, we sit down with John Marlowe and Pete Kane to explore how patient-driven innovation is transforming research on rare diseases and oncology. John shares his own 15-year medical odyssey filled with misdiagnoses and being told his symptoms were “in his head” and how his relentless determination led him to long-read sequencing which finally revealed his rare disease diagnosis. Pete, founder of Research to the People, explains how his nonprofit brings together scientists, engineers, and patients in open hackathons to tackle unsolved medical mysteries.<br />Together, John and Pete reveal what happens when “scientific cowboys and cowgirls” unite—merging cutting-edge genomics, AI, and the power of community and collaboration to push the boundaries of diagnosis and treatment. Their story is a powerful reminder that the future of biotech is not just about technology but about people coming together to rewrite what’s possible. </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 17 Sep 2025 16:00:00 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Daniel Arce, Serena Gao, Danielle Luu, Amaryllis Tsiknia, Daniel Graves, Katherine Merkling, Bryan Jimenez, Stephanie Wu)</author>
      <link>https://inside-biotech.simplecast.com/episodes/diagnosing-the-undiagnosed-john-marlow-and-pete-kane-of-research-to-the-people-b27Inrik</link>
      <content:encoded><![CDATA[<p>In this episode of Inside Biotech, we sit down with John Marlowe and Pete Kane to explore how patient-driven innovation is transforming research on rare diseases and oncology. John shares his own 15-year medical odyssey filled with misdiagnoses and being told his symptoms were “in his head” and how his relentless determination led him to long-read sequencing which finally revealed his rare disease diagnosis. Pete, founder of Research to the People, explains how his nonprofit brings together scientists, engineers, and patients in open hackathons to tackle unsolved medical mysteries.<br />Together, John and Pete reveal what happens when “scientific cowboys and cowgirls” unite—merging cutting-edge genomics, AI, and the power of community and collaboration to push the boundaries of diagnosis and treatment. Their story is a powerful reminder that the future of biotech is not just about technology but about people coming together to rewrite what’s possible. </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="51377257" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/ac60dd0f-c015-4813-8f41-57a8f86b8b3c/audio/5e7688a8-8a67-4ba5-a089-c35d709a4731/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Diagnosing the Undiagnosed: John Marlow and Pete Kane of Research to the People</itunes:title>
      <itunes:author>Gabriella Rubert, Daniel Arce, Serena Gao, Danielle Luu, Amaryllis Tsiknia, Daniel Graves, Katherine Merkling, Bryan Jimenez, Stephanie Wu</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/319060fd-a035-45b3-b857-46d68c460ed4/3000x3000/square-20bcla-johnandpete.jpg?aid=rss_feed"/>
      <itunes:duration>00:53:31</itunes:duration>
      <itunes:summary>In this episode of Inside Biotech, we sit down with John Marlowe and Pete Kane to explore how patient-driven innovation is transforming research on rare diseases and oncology. John shares his own 15-year medical odyssey filled with misdiagnoses and being told his symptoms were “in his head” and how his relentless determination led him to long-read sequencing which finally revealed his rare disease diagnosis. Pete, founder of Research to the People, explains how his nonprofit brings together scientists, engineers, and patients in open hackathons to tackle unsolved medical mysteries.
Together, John and Pete reveal what happens when “scientific cowboys and cowgirls” unite—merging cutting-edge genomics, AI, and the power of community and collaboration to push the boundaries of diagnosis and treatment. Their story is a powerful reminder that the future of biotech is not just about technology, but about people coming together to rewrite what’s possible. 
</itunes:summary>
      <itunes:subtitle>In this episode of Inside Biotech, we sit down with John Marlowe and Pete Kane to explore how patient-driven innovation is transforming research on rare diseases and oncology. John shares his own 15-year medical odyssey filled with misdiagnoses and being told his symptoms were “in his head” and how his relentless determination led him to long-read sequencing which finally revealed his rare disease diagnosis. Pete, founder of Research to the People, explains how his nonprofit brings together scientists, engineers, and patients in open hackathons to tackle unsolved medical mysteries.
Together, John and Pete reveal what happens when “scientific cowboys and cowgirls” unite—merging cutting-edge genomics, AI, and the power of community and collaboration to push the boundaries of diagnosis and treatment. Their story is a powerful reminder that the future of biotech is not just about technology, but about people coming together to rewrite what’s possible. 
</itunes:subtitle>
      <itunes:keywords>inside biotech, biotech, bcla, rare disease</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>33</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">7627f434-f32e-474f-854d-4edd2c0e5e56</guid>
      <title>The AI Revolution in Drug Development with Jennifer Bittinger, President and Co-founder of Narrativa</title>
      <description><![CDATA[<p>From TV production to trailblazing in generative AI, Jennifer Bittinger’s journey is anything but ordinary. In this episode of Inside Biotech, Jennifer shares how her non-linear career path–from helping launch Hulu to leading Narrativa–prepared her to bring AI innovation into the life sciences. She reveals how Narrativa became the first company to have FDA-approved, AI-generated clinical trial documentation, cutting years of “white space” in the drug-development process. Along the way, she tackles fears about AI replacing jobs, explaining how it can instead give scientists and medical writers their time back for high-value work. Today’s episode is a masterclass in how relationships, curiosity, and a little bit of courage can transform entire industries.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Thu, 21 Aug 2025 15:00:00 +0000</pubDate>
      <author>team@bc-la.org (Amaryllis Tsiknia, Kat Merkling, Bryan Jimenez, Gabriella Rubert, Daniel Graves, Danielle Luu, Serena Gao, Daniel Arce, Stephanie Wu)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-ai-revolution-in-drug-development-with-jennifer-bittinger-ceo-of-narrativa-EDAPb4UP</link>
      <content:encoded><![CDATA[<p>From TV production to trailblazing in generative AI, Jennifer Bittinger’s journey is anything but ordinary. In this episode of Inside Biotech, Jennifer shares how her non-linear career path–from helping launch Hulu to leading Narrativa–prepared her to bring AI innovation into the life sciences. She reveals how Narrativa became the first company to have FDA-approved, AI-generated clinical trial documentation, cutting years of “white space” in the drug-development process. Along the way, she tackles fears about AI replacing jobs, explaining how it can instead give scientists and medical writers their time back for high-value work. Today’s episode is a masterclass in how relationships, curiosity, and a little bit of courage can transform entire industries.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="26817951" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/ff73342c-7934-415f-98bd-add42d5358ee/audio/61d1d80a-cb67-44b2-bcde-80b961b3908b/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The AI Revolution in Drug Development with Jennifer Bittinger, President and Co-founder of Narrativa</itunes:title>
      <itunes:author>Amaryllis Tsiknia, Kat Merkling, Bryan Jimenez, Gabriella Rubert, Daniel Graves, Danielle Luu, Serena Gao, Daniel Arce, Stephanie Wu</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/c3a15e37-81c4-4cfa-b774-5ee2014ec38d/3000x3000/jennifer-flyer.jpg?aid=rss_feed"/>
      <itunes:duration>00:55:52</itunes:duration>
      <itunes:summary>From TV production to trailblazing in generative AI, Jennifer Bittinger’s journey is anything but ordinary. In this episode of Inside Biotech, Jennifer shares how her non-linear career path–from helping launch Hulu to leading Narrativa–prepared her to bring AI innovation into the life sciences. She reveals how Narrativa became the first company to have FDA-approved, AI-generated clinical trial documentation, cutting years of “white space” in the drug-development process. Along the way, she tackles fears about AI replacing jobs, explaining how it can instead give scientists and medical writers their time back for high-value work. Today’s episode is a masterclass in how relationships, curiosity, and a little bit of courage can transform entire industries.
</itunes:summary>
      <itunes:subtitle>From TV production to trailblazing in generative AI, Jennifer Bittinger’s journey is anything but ordinary. In this episode of Inside Biotech, Jennifer shares how her non-linear career path–from helping launch Hulu to leading Narrativa–prepared her to bring AI innovation into the life sciences. She reveals how Narrativa became the first company to have FDA-approved, AI-generated clinical trial documentation, cutting years of “white space” in the drug-development process. Along the way, she tackles fears about AI replacing jobs, explaining how it can instead give scientists and medical writers their time back for high-value work. Today’s episode is a masterclass in how relationships, curiosity, and a little bit of courage can transform entire industries.
</itunes:subtitle>
      <itunes:keywords>inside biotech, biotech, bcla, ai, startup</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>32</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">b275b8bd-929e-49bb-a67c-d9745e0de99c</guid>
      <title>The Biotech Hiring Secret Sauce with Colin Smith, ExecNow CEO</title>
      <description><![CDATA[<p>Biotech is bursting with innovation—from gene editing to AI-powered diagnostics—but behind every successful breakthrough is something far less talked about: leadership. In this episode of Inside Biotech, we’re joined by Colin Smith, CEO and co-founder of ExecNow, a next-gen talent partner helping some of the world’s most innovative biotech, greentech, and AI companies find the leaders they need to scale science into sustainable businesses.<br />Colin has spent years working behind the scenes, partnering with founders to solve one of the industry’s toughest challenges: bridging the divide between scientific genius and business execution. He shares insights on why many brilliant biotech companies struggle—not because of flawed science, but because they lack the right leadership to guide them through growth, regulation, commercialization, and culture-building.<br />We dive into why the industry struggles to attract diverse and strategic leaders, how values-based hiring makes a difference, and why a clear mission can be a company’s strongest competitive advantage. Whether you’re a founder, a scientist, or just curious about the human side of biotech, this conversation reveals what it really takes to build companies that not only survive, but lead.</p><p>(0:00) Intro to Colin Smith CEO of ExecNow<br />(2:25) What is Colin Smith’s general background in biotech?<br />(3:36) What caused Colin to go into talent acquisition?<br />(6:41) The importance of a diverse workforce talent<br />(7:40) How to demonstrate that you have the skills to work in biotech?<br />(9:40) Tell people the story of your career.<br />(12:25) Is professional work life just a group project?<br />(14:04) What does ExecNow’s statement “Build by operators for operators mean?”<br />(16:50) Give some examples of how leadership position priority changes across different funding stages?<br />(19:39) Top talent wants to work with top talent<br />(23:10) Common pitfalls in companies and do they differ across Biotech vs. MedTech?<br />(25:50) How does capital play into company development?<br />(27:52) Few and Far Between Biotech Podcast Ad<br />(28:27) Any topics that surprised Colin with their innovation?<br />(31:23) What are workers main drivers in their career?<br />(33:28) Need to leverage AI on a daily basis.<br />(35:50) Useful idea to use LLM to figure out what biotech companies just received funding and how to contact their hiring managers to see if a job is available.<br />(36:50) How do I find a job to create a trajectory for a fulfilling career?<br />(38:45) How to stick out and not “boil the ocean” and find a job in biotech.<br />(42:10) Noone’s career is up and to the right (in graph speaking)<br />(46:50) How does Gabriella look towards her career when she graduates from her PhD?<br />(51:26) Wrap up thanking Colin Smith CEO from ExecNow</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 18 Jun 2025 14:00:00 +0000</pubDate>
      <author>team@bc-la.org (Daniel Arce, Daniel Graves, Danielle Luu, Bryan Jimenez, Serena Gao, Gabriella Rubert, Kat Merkling, Stephanie Wu)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-biotech-hiring-secret-sauce-with-colin-smith-execnow-ceo-39A5H29c</link>
      <content:encoded><![CDATA[<p>Biotech is bursting with innovation—from gene editing to AI-powered diagnostics—but behind every successful breakthrough is something far less talked about: leadership. In this episode of Inside Biotech, we’re joined by Colin Smith, CEO and co-founder of ExecNow, a next-gen talent partner helping some of the world’s most innovative biotech, greentech, and AI companies find the leaders they need to scale science into sustainable businesses.<br />Colin has spent years working behind the scenes, partnering with founders to solve one of the industry’s toughest challenges: bridging the divide between scientific genius and business execution. He shares insights on why many brilliant biotech companies struggle—not because of flawed science, but because they lack the right leadership to guide them through growth, regulation, commercialization, and culture-building.<br />We dive into why the industry struggles to attract diverse and strategic leaders, how values-based hiring makes a difference, and why a clear mission can be a company’s strongest competitive advantage. Whether you’re a founder, a scientist, or just curious about the human side of biotech, this conversation reveals what it really takes to build companies that not only survive, but lead.</p><p>(0:00) Intro to Colin Smith CEO of ExecNow<br />(2:25) What is Colin Smith’s general background in biotech?<br />(3:36) What caused Colin to go into talent acquisition?<br />(6:41) The importance of a diverse workforce talent<br />(7:40) How to demonstrate that you have the skills to work in biotech?<br />(9:40) Tell people the story of your career.<br />(12:25) Is professional work life just a group project?<br />(14:04) What does ExecNow’s statement “Build by operators for operators mean?”<br />(16:50) Give some examples of how leadership position priority changes across different funding stages?<br />(19:39) Top talent wants to work with top talent<br />(23:10) Common pitfalls in companies and do they differ across Biotech vs. MedTech?<br />(25:50) How does capital play into company development?<br />(27:52) Few and Far Between Biotech Podcast Ad<br />(28:27) Any topics that surprised Colin with their innovation?<br />(31:23) What are workers main drivers in their career?<br />(33:28) Need to leverage AI on a daily basis.<br />(35:50) Useful idea to use LLM to figure out what biotech companies just received funding and how to contact their hiring managers to see if a job is available.<br />(36:50) How do I find a job to create a trajectory for a fulfilling career?<br />(38:45) How to stick out and not “boil the ocean” and find a job in biotech.<br />(42:10) Noone’s career is up and to the right (in graph speaking)<br />(46:50) How does Gabriella look towards her career when she graduates from her PhD?<br />(51:26) Wrap up thanking Colin Smith CEO from ExecNow</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="50814548" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/4d100548-c0ef-4c2a-a82f-b3955c865883/audio/437d584f-f1a4-4ff3-9f1b-434213e6f470/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The Biotech Hiring Secret Sauce with Colin Smith, ExecNow CEO</itunes:title>
      <itunes:author>Daniel Arce, Daniel Graves, Danielle Luu, Bryan Jimenez, Serena Gao, Gabriella Rubert, Kat Merkling, Stephanie Wu</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/03bd172e-2edf-4399-93bc-5f481bca4859/3000x3000/colin-20smith-20-20-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:52:55</itunes:duration>
      <itunes:summary>Biotech is bursting with innovation—from gene editing to AI-powered diagnostics—but behind every successful breakthrough is something far less talked about: leadership. In this episode of Inside Biotech, we’re joined by Colin Smith, CEO and co-founder of ExecNow, a next-gen talent partner helping some of the world’s most innovative biotech, greentech, and AI companies find the leaders they need to scale science into sustainable businesses.
Colin has spent years working behind the scenes, partnering with founders to solve one of the industry’s toughest challenges: bridging the divide between scientific genius and business execution. He shares insights on why many brilliant biotech companies struggle—not because of flawed science, but because they lack the right leadership to guide them through growth, regulation, commercialization, and culture-building.
We dive into why the industry struggles to attract diverse and strategic leaders, how values-based hiring makes a difference, and why a clear mission can be a company’s strongest competitive advantage. Whether you’re a founder, a scientist, or just curious about the human side of biotech, this conversation reveals what it really takes to build companies that not only survive, but lead.
(0:00) Intro to Colin Smith CEO of ExecNow
(2:25) What is Colin Smith’s general background in biotech?
(3:36) What caused Colin to go into talent acquisition?
(6:41) The importance of a diverse workforce talent
(7:40) How to demonstrate that you have the skills to work in biotech?
(9:40) Tell people the story of your career.
(12:25) Is professional work life just a group project?
(14:04) What does ExecNow’s statement “Build by operators for operators mean?”
(16:50) Give some examples of how leadership position priority changes across different funding stages?
(19:39) Top talent wants to work with top talent
(23:10) Common pitfalls in companies and do they differ across Biotech vs. MedTech?
(25:50) How does capital play into company development?
(27:52) Few and Far Between Biotech Podcast Ad
(28:27) Any topics that surprised Colin with their innovation?
(31:23) What are workers main drivers in their career?
(33:28) Need to leverage AI on a daily basis.
(35:50) Useful idea to use LLM to figure out what biotech companies just received funding and how to contact their hiring managers to see if a job is available.
(36:50) How do I find a job to create a trajectory for a fulfilling career?
(38:45) How to stick out and not “boil the ocean” and find a job in biotech.
(42:10) Noone’s career is up and to the right (in graph speaking)
(46:50) How does Gabriella look towards her career when she graduates from her PhD?
(51:26) Wrap up thanking Colin Smith CEO from ExecNow
</itunes:summary>
      <itunes:subtitle>Biotech is bursting with innovation—from gene editing to AI-powered diagnostics—but behind every successful breakthrough is something far less talked about: leadership. In this episode of Inside Biotech, we’re joined by Colin Smith, CEO and co-founder of ExecNow, a next-gen talent partner helping some of the world’s most innovative biotech, greentech, and AI companies find the leaders they need to scale science into sustainable businesses.
Colin has spent years working behind the scenes, partnering with founders to solve one of the industry’s toughest challenges: bridging the divide between scientific genius and business execution. He shares insights on why many brilliant biotech companies struggle—not because of flawed science, but because they lack the right leadership to guide them through growth, regulation, commercialization, and culture-building.
We dive into why the industry struggles to attract diverse and strategic leaders, how values-based hiring makes a difference, and why a clear mission can be a company’s strongest competitive advantage. Whether you’re a founder, a scientist, or just curious about the human side of biotech, this conversation reveals what it really takes to build companies that not only survive, but lead.
(0:00) Intro to Colin Smith CEO of ExecNow
(2:25) What is Colin Smith’s general background in biotech?
(3:36) What caused Colin to go into talent acquisition?
(6:41) The importance of a diverse workforce talent
(7:40) How to demonstrate that you have the skills to work in biotech?
(9:40) Tell people the story of your career.
(12:25) Is professional work life just a group project?
(14:04) What does ExecNow’s statement “Build by operators for operators mean?”
(16:50) Give some examples of how leadership position priority changes across different funding stages?
(19:39) Top talent wants to work with top talent
(23:10) Common pitfalls in companies and do they differ across Biotech vs. MedTech?
(25:50) How does capital play into company development?
(27:52) Few and Far Between Biotech Podcast Ad
(28:27) Any topics that surprised Colin with their innovation?
(31:23) What are workers main drivers in their career?
(33:28) Need to leverage AI on a daily basis.
(35:50) Useful idea to use LLM to figure out what biotech companies just received funding and how to contact their hiring managers to see if a job is available.
(36:50) How do I find a job to create a trajectory for a fulfilling career?
(38:45) How to stick out and not “boil the ocean” and find a job in biotech.
(42:10) Noone’s career is up and to the right (in graph speaking)
(46:50) How does Gabriella look towards her career when she graduates from her PhD?
(51:26) Wrap up thanking Colin Smith CEO from ExecNow
</itunes:subtitle>
      <itunes:keywords>hiring, biotech, bcla, career transition</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>31</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">ea3fed4c-09d1-4fdd-abaa-577a88fdbda9</guid>
      <title>CRISPR Campaigns &amp; Beyond: Science Marketing with Elizabeth Chabe, Founder/CEO of High Touch Group</title>
      <description><![CDATA[<p>What does it really take to bring cutting-edge science out of the lab and into the world? In this episode of Inside Biotech, we sit down with Elizabeth Chabe, founder and CEO of High Touch Group, a strategic marketing firm specializing in biotech, medtech, and deep tech.<br />Elizabeth shares her unique journey—from working in a structural engineering lab and helping scale pilot manufacturing projects, to becoming a trusted advisor to venture-backed startups across the life sciences. Along the way, she’s led national campaigns at institutions like The Jackson Laboratory, helped scientists secure critical funding, and built a business that helps translate complex science into commercial success.<br />Whether you’re a researcher, founder, or science communicator, Elizabeth offers actionable advice on how to make sure your innovation doesn’t stay hidden in the lab.</p><p>(0:00) Intro to Elizabeth Chabe<br />(1:52) City of Hope Ad<br />(2:34) Welcome to Elizabeth Chabe CEO of High Tough Group<br />(3:57) Elizabeth background starting first business at age 9 as a psychic hotline! Elizabeth had a wide entrepreneurship business at a young age.<br />(7:42) How to translate entrepreneurism to science?<br />(11:28) Challenges working at Jackson Lab during beginning of CRISPR.<br />(18:00) Most important moments in marketing are founding teams and adventures.<br />(21:40) Few and Far Between Podcast Ad<br />(22:30) How was High Touch Group started?<br />(29:12) What did client recruitment look like pre JAX and post JAX?<br />(36:32) Focus of High Tough Group clients.<br />(40:28) How does Elizabeth determine how best to help High Touch Group Clients Initially?<br />(45:58) Motivation for writing The Giant’s Ladder?<br />(49:20) Advice to early career scientists to get out and communicate?<br />(55:40) Outro</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 21 May 2025 16:09:37 +0000</pubDate>
      <author>team@bc-la.org (Bryan Jimenez, Gabriella Rubert, Daniel Arce, Kat Merkling, Daniel Graves, Serena Gao)</author>
      <link>https://inside-biotech.simplecast.com/episodes/crispr-campaigns-beyond-science-marketing-with-elizabeth-chabe-founder-ceo-of-high-touch-group-zyyB68iJ</link>
      <content:encoded><![CDATA[<p>What does it really take to bring cutting-edge science out of the lab and into the world? In this episode of Inside Biotech, we sit down with Elizabeth Chabe, founder and CEO of High Touch Group, a strategic marketing firm specializing in biotech, medtech, and deep tech.<br />Elizabeth shares her unique journey—from working in a structural engineering lab and helping scale pilot manufacturing projects, to becoming a trusted advisor to venture-backed startups across the life sciences. Along the way, she’s led national campaigns at institutions like The Jackson Laboratory, helped scientists secure critical funding, and built a business that helps translate complex science into commercial success.<br />Whether you’re a researcher, founder, or science communicator, Elizabeth offers actionable advice on how to make sure your innovation doesn’t stay hidden in the lab.</p><p>(0:00) Intro to Elizabeth Chabe<br />(1:52) City of Hope Ad<br />(2:34) Welcome to Elizabeth Chabe CEO of High Tough Group<br />(3:57) Elizabeth background starting first business at age 9 as a psychic hotline! Elizabeth had a wide entrepreneurship business at a young age.<br />(7:42) How to translate entrepreneurism to science?<br />(11:28) Challenges working at Jackson Lab during beginning of CRISPR.<br />(18:00) Most important moments in marketing are founding teams and adventures.<br />(21:40) Few and Far Between Podcast Ad<br />(22:30) How was High Touch Group started?<br />(29:12) What did client recruitment look like pre JAX and post JAX?<br />(36:32) Focus of High Tough Group clients.<br />(40:28) How does Elizabeth determine how best to help High Touch Group Clients Initially?<br />(45:58) Motivation for writing The Giant’s Ladder?<br />(49:20) Advice to early career scientists to get out and communicate?<br />(55:40) Outro</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="54650576" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/b235f941-f8ee-4f38-9dc3-f05fcc5f7770/audio/af01c4b0-0208-42da-a6c4-36d86aa1159d/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>CRISPR Campaigns &amp; Beyond: Science Marketing with Elizabeth Chabe, Founder/CEO of High Touch Group</itunes:title>
      <itunes:author>Bryan Jimenez, Gabriella Rubert, Daniel Arce, Kat Merkling, Daniel Graves, Serena Gao</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/728c7b8c-3e17-4e33-b1ec-1bac79770e85/3000x3000/elizabethchabe.jpg?aid=rss_feed"/>
      <itunes:duration>00:56:55</itunes:duration>
      <itunes:summary>What does it really take to bring cutting-edge science out of the lab and into the world? In this episode of Inside Biotech, we sit down with Elizabeth Chabe, founder and CEO of High Touch Group, a strategic marketing firm specializing in biotech, medtech, and deep tech.
Elizabeth shares her unique journey—from working in a structural engineering lab and helping scale pilot manufacturing projects, to becoming a trusted advisor to venture-backed startups across the life sciences. Along the way, she’s led national campaigns at institutions like The Jackson Laboratory, helped scientists secure critical funding, and built a business that helps translate complex science into commercial success.
Whether you’re a researcher, founder, or science communicator, Elizabeth offers actionable advice on how to make sure your innovation doesn’t stay hidden in the lab.

(0:00) Intro to Elizabeth Chabe
(1:52) City of Hope Ad
(2:34) Welcome to Elizabeth Chabe CEO of High Tough Group
(3:57) Elizabeth background starting first business at age 9 as a psychic hotline! Elizabeth had a wide entrepreneurship business at a young age.
(7:42) How to translate entrepreneurism to science?
(11:28) Challenges working at Jackson Lab during beginning of CRISPR.
(18:00) Most important moments in marketing are founding teams and adventures.
(21:40) Few and Far Between Podcast Ad
(22:30) How was High Touch Group started?
(29:12) What did client recruitment look like pre JAX and post JAX?
(36:32) Focus of High Tough Group clients.
(40:28) How does Elizabeth determine how best to help High Touch Group Clients Initially?
(45:58) Motivation for writing The Giant’s Ladder?
(49:20) Advice to early career scientists to get out and communicate?
(55:40) Outro

</itunes:summary>
      <itunes:subtitle>What does it really take to bring cutting-edge science out of the lab and into the world? In this episode of Inside Biotech, we sit down with Elizabeth Chabe, founder and CEO of High Touch Group, a strategic marketing firm specializing in biotech, medtech, and deep tech.
Elizabeth shares her unique journey—from working in a structural engineering lab and helping scale pilot manufacturing projects, to becoming a trusted advisor to venture-backed startups across the life sciences. Along the way, she’s led national campaigns at institutions like The Jackson Laboratory, helped scientists secure critical funding, and built a business that helps translate complex science into commercial success.
Whether you’re a researcher, founder, or science communicator, Elizabeth offers actionable advice on how to make sure your innovation doesn’t stay hidden in the lab.

(0:00) Intro to Elizabeth Chabe
(1:52) City of Hope Ad
(2:34) Welcome to Elizabeth Chabe CEO of High Tough Group
(3:57) Elizabeth background starting first business at age 9 as a psychic hotline! Elizabeth had a wide entrepreneurship business at a young age.
(7:42) How to translate entrepreneurism to science?
(11:28) Challenges working at Jackson Lab during beginning of CRISPR.
(18:00) Most important moments in marketing are founding teams and adventures.
(21:40) Few and Far Between Podcast Ad
(22:30) How was High Touch Group started?
(29:12) What did client recruitment look like pre JAX and post JAX?
(36:32) Focus of High Tough Group clients.
(40:28) How does Elizabeth determine how best to help High Touch Group Clients Initially?
(45:58) Motivation for writing The Giant’s Ladder?
(49:20) Advice to early career scientists to get out and communicate?
(55:40) Outro

</itunes:subtitle>
      <itunes:keywords>science communication, science-storytelling, inside biotech, science marketing, biotech, bcla, startup</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>30</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">cd523d87-ffbc-4a69-8fdc-76849486b324</guid>
      <title>From Neuroscience to OmBiome: Dr. Julia Perederiy on Building a Science-Backed Wellness Brand</title>
      <description><![CDATA[<p>In this episode of Inside Biotech, we sit down with Dr. Julia Perederiy, neuroscientist and Founder of OmBiome, a regenerative health company revolutionizing personal care through microalgae. Julia shares her journey from academia to entrepreneurship, the science behind her mission, and how wellness trends are evolving in today’s market. Tune in for insights on building a biotech-driven wellness brand and how algae could shape the future of holistic health.</p><p>(0:00) Intro to this months episode with Dr. Julia Perederiy from OmBiome!<br />(1:35) City of Hope Ad<br />(2:13) Greeting Dr. Julia Perederiy from OmBiome<br />(2:57) OmBiome is a regenerative health company using algae for oral health<br />(4:08) What inspired Julia to start a company in the wellness space<br />(5:50) What is the line between a therapeutic and a wellness supplement?<br />(7:13) Strict language to as wellness products cannot “treat” disease, but can support them.<br />(8:40) How to define OmBiome’s success?<br />(10:30) Julia hopes that this “wellness” focus will shift to a Biotech company<br />(11:59) What is the marketing strategy for OmBiome?<br />(15:02) What is Julia’s background in science?<br />(17:50) How did Julia get from neuroscience to OmBiome’s focus on nutrition and the microenvironment<br />(23:10) How effective vs. mechanism for how OmBiome improves the mouth.<br />(24:00) Nobody cares about science of how things work, but they care about how to meet unmet need.<br />(28:25) Importance of having whole foods rather than additive Vitamins.<br />(30:05) Basis for gum disease<br />(31:28) What is the first step towards starting OmBiome?<br />(35:38) Statistics in dental health are really powerful indicators that most adults have gum disease and many children have cavities.<br />(37:22) Spirulina in the supplement industry.<br />(38:50) Julia came to the United States from Russia at the age of 12.<br />(42:10) Esoteric terms in a different fields like science, business, wellness, etc.<br />(43:40) Where is the wellness industry going in the next 10 years?<br />(49:02) We do not need every minute detail of science answered to help humanity.<br />(50:35) Wrap up of episode with Dr. Julia Perederiy</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 16 Apr 2025 15:00:00 +0000</pubDate>
      <author>team@bc-la.org (Bryan Jimenez, Daniel Graves, Daniel Arce, Kat Merkling, Serena Gao, Gabriella Rubert)</author>
      <link>https://inside-biotech.simplecast.com/episodes/from-neuroscience-to-ombiome-dr-julia-perederiy-on-building-a-science-backed-wellness-brand-32wYBUx4</link>
      <content:encoded><![CDATA[<p>In this episode of Inside Biotech, we sit down with Dr. Julia Perederiy, neuroscientist and Founder of OmBiome, a regenerative health company revolutionizing personal care through microalgae. Julia shares her journey from academia to entrepreneurship, the science behind her mission, and how wellness trends are evolving in today’s market. Tune in for insights on building a biotech-driven wellness brand and how algae could shape the future of holistic health.</p><p>(0:00) Intro to this months episode with Dr. Julia Perederiy from OmBiome!<br />(1:35) City of Hope Ad<br />(2:13) Greeting Dr. Julia Perederiy from OmBiome<br />(2:57) OmBiome is a regenerative health company using algae for oral health<br />(4:08) What inspired Julia to start a company in the wellness space<br />(5:50) What is the line between a therapeutic and a wellness supplement?<br />(7:13) Strict language to as wellness products cannot “treat” disease, but can support them.<br />(8:40) How to define OmBiome’s success?<br />(10:30) Julia hopes that this “wellness” focus will shift to a Biotech company<br />(11:59) What is the marketing strategy for OmBiome?<br />(15:02) What is Julia’s background in science?<br />(17:50) How did Julia get from neuroscience to OmBiome’s focus on nutrition and the microenvironment<br />(23:10) How effective vs. mechanism for how OmBiome improves the mouth.<br />(24:00) Nobody cares about science of how things work, but they care about how to meet unmet need.<br />(28:25) Importance of having whole foods rather than additive Vitamins.<br />(30:05) Basis for gum disease<br />(31:28) What is the first step towards starting OmBiome?<br />(35:38) Statistics in dental health are really powerful indicators that most adults have gum disease and many children have cavities.<br />(37:22) Spirulina in the supplement industry.<br />(38:50) Julia came to the United States from Russia at the age of 12.<br />(42:10) Esoteric terms in a different fields like science, business, wellness, etc.<br />(43:40) Where is the wellness industry going in the next 10 years?<br />(49:02) We do not need every minute detail of science answered to help humanity.<br />(50:35) Wrap up of episode with Dr. Julia Perederiy</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="50022932" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/eee6f524-73a4-49dd-884c-b35b5870164e/audio/4b238fe4-533e-4e99-a1ec-71711fc8dd59/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>From Neuroscience to OmBiome: Dr. Julia Perederiy on Building a Science-Backed Wellness Brand</itunes:title>
      <itunes:author>Bryan Jimenez, Daniel Graves, Daniel Arce, Kat Merkling, Serena Gao, Gabriella Rubert</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/e1fd13c3-e776-414f-93b3-67e8c718661b/3000x3000/ib-julia-20flyer.jpg?aid=rss_feed"/>
      <itunes:duration>00:52:06</itunes:duration>
      <itunes:summary>In this episode of Inside Biotech, we sit down with Dr. Julia Perederiy, neuroscientist and Founder of OmBiome, a regenerative health company revolutionizing personal care through microalgae. Julia shares her journey from academia to entrepreneurship, the science behind her mission, and how wellness trends are evolving in today’s market. Tune in for insights on building a biotech-driven wellness brand and how algae could shape the future of holistic health.

(0:00) Intro to this months episode with Dr. Julia Perederiy from OmBiome!
(1:35) City of Hope Ad
(2:13) Greeting Dr. Julia Perederiy from OmBiome
(2:57) OmBiome is a regenerative health company using algae for oral health
(4:08) What inspired Julia to start a company in the wellness space
(5:50) What is the line between a therapeutic and a wellness supplement?
(7:13) Strict language to as wellness products cannot “treat” disease, but can support them.
(8:40) How to define OmBiome’s success?
(10:30) Julia hopes that this “wellness” focus will shift to a Biotech company
(11:59) What is the marketing strategy for OmBiome?
(15:02) What is Julia’s background in science?
(17:50) How did Julia get from neuroscience to OmBiome’s focus on nutrition and the microenvironment
(23:10) How effective vs. mechanism for how OmBiome improves the mouth.
(24:00) Nobody cares about science of how things work, but they care about how to meet unmet need.
(28:25) Importance of having whole foods rather than additive Vitamins.
(30:05) Basis for gum disease
(31:28) What is the first step towards starting OmBiome? 
(35:38) Statistics in dental health are really powerful indicators that most adults have gum disease and many children have cavities. 
(37:22) Spirulina in the supplement industry.
(38:50) Julia came to the United States from Russia at the age of 12. 
(42:10) Esoteric terms in a different fields like science, business, wellness, etc. 
(43:40) Where is the wellness industry going in the next 10 years?
(49:02) We do not need every minute detail of science answered to help humanity. 
(50:35) Wrap up of episode with Dr. Julia Perederiy
</itunes:summary>
      <itunes:subtitle>In this episode of Inside Biotech, we sit down with Dr. Julia Perederiy, neuroscientist and Founder of OmBiome, a regenerative health company revolutionizing personal care through microalgae. Julia shares her journey from academia to entrepreneurship, the science behind her mission, and how wellness trends are evolving in today’s market. Tune in for insights on building a biotech-driven wellness brand and how algae could shape the future of holistic health.

(0:00) Intro to this months episode with Dr. Julia Perederiy from OmBiome!
(1:35) City of Hope Ad
(2:13) Greeting Dr. Julia Perederiy from OmBiome
(2:57) OmBiome is a regenerative health company using algae for oral health
(4:08) What inspired Julia to start a company in the wellness space
(5:50) What is the line between a therapeutic and a wellness supplement?
(7:13) Strict language to as wellness products cannot “treat” disease, but can support them.
(8:40) How to define OmBiome’s success?
(10:30) Julia hopes that this “wellness” focus will shift to a Biotech company
(11:59) What is the marketing strategy for OmBiome?
(15:02) What is Julia’s background in science?
(17:50) How did Julia get from neuroscience to OmBiome’s focus on nutrition and the microenvironment
(23:10) How effective vs. mechanism for how OmBiome improves the mouth.
(24:00) Nobody cares about science of how things work, but they care about how to meet unmet need.
(28:25) Importance of having whole foods rather than additive Vitamins.
(30:05) Basis for gum disease
(31:28) What is the first step towards starting OmBiome? 
(35:38) Statistics in dental health are really powerful indicators that most adults have gum disease and many children have cavities. 
(37:22) Spirulina in the supplement industry.
(38:50) Julia came to the United States from Russia at the age of 12. 
(42:10) Esoteric terms in a different fields like science, business, wellness, etc. 
(43:40) Where is the wellness industry going in the next 10 years?
(49:02) We do not need every minute detail of science answered to help humanity. 
(50:35) Wrap up of episode with Dr. Julia Perederiy
</itunes:subtitle>
      <itunes:keywords>inside biotech, biotech, bcla, consumer wellness, startup</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>29</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">22380181-2e47-481f-b4ce-476fc1d562ea</guid>
      <title>Repurposing Drugs &amp; Reinventing Biotech: Dr. Adam Watson on Building MeCo Diagnostics</title>
      <description><![CDATA[<p>In this discussion, Dr. Adam Watson, Co-founder and CEO of MeCo Diagnostics, shares the personal and professional experiences that led him to focus on cancer research and, ultimately, to launch his own company. From the profound influence of his family’s battle with cancer to the long and complex journey of developing the MeCo Score™, he walks us through the challenges of translating academic research into a commercial product. Dr. Watson offers insights into the realities of working with a tech transfer office, the hurdles of bringing a biomarker test to market, and the tough decision of leaving academia to pursue entrepreneurship. He also reflects on the knowledge gaps he faced as a first-time founder and the strategies that helped MeCo gain credibility in an industry dominated by large pharmaceutical companies. Finally, we discuss the broader biotech landscape—how LA’s biotech ecosystem can better support startups like MeCo, and what it will take for non–big pharma breakthroughs to gain traction in the market. Whether you're a scientist considering a leap into entrepreneurship or someone interested in the future of precision medicine, this conversation offers valuable lessons in perseverance, innovation, and the intersection of science and business.<br /><a href="https://mecodiagnostics.com/">https://mecodiagnostics.com/</a> </p><p>RSVP for BCLA 10th Annual Healthcare Summit: <a href="https://lu.ma/pecqtqut">https://lu.ma/pecqtqut</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Fri, 7 Mar 2025 18:00:00 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Daniel Graves, Serena Gao, Bryan Jimenez, Katherine Merkling, Daniel Arce)</author>
      <link>https://inside-biotech.simplecast.com/episodes/repurposing-drugs-reinventing-biotech-dr-adam-watson-on-building-meco-diagnostics-HE_njfKj</link>
      <content:encoded><![CDATA[<p>In this discussion, Dr. Adam Watson, Co-founder and CEO of MeCo Diagnostics, shares the personal and professional experiences that led him to focus on cancer research and, ultimately, to launch his own company. From the profound influence of his family’s battle with cancer to the long and complex journey of developing the MeCo Score™, he walks us through the challenges of translating academic research into a commercial product. Dr. Watson offers insights into the realities of working with a tech transfer office, the hurdles of bringing a biomarker test to market, and the tough decision of leaving academia to pursue entrepreneurship. He also reflects on the knowledge gaps he faced as a first-time founder and the strategies that helped MeCo gain credibility in an industry dominated by large pharmaceutical companies. Finally, we discuss the broader biotech landscape—how LA’s biotech ecosystem can better support startups like MeCo, and what it will take for non–big pharma breakthroughs to gain traction in the market. Whether you're a scientist considering a leap into entrepreneurship or someone interested in the future of precision medicine, this conversation offers valuable lessons in perseverance, innovation, and the intersection of science and business.<br /><a href="https://mecodiagnostics.com/">https://mecodiagnostics.com/</a> </p><p>RSVP for BCLA 10th Annual Healthcare Summit: <a href="https://lu.ma/pecqtqut">https://lu.ma/pecqtqut</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="57478070" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/48574415-1037-458c-88b1-e432cb918a4c/audio/1431eead-bdb5-4824-ba04-9ecc02c6e05c/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Repurposing Drugs &amp; Reinventing Biotech: Dr. Adam Watson on Building MeCo Diagnostics</itunes:title>
      <itunes:author>Gabriella Rubert, Daniel Graves, Serena Gao, Bryan Jimenez, Katherine Merkling, Daniel Arce</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/c43e7fda-83b8-45d4-807c-79f902e523b8/3000x3000/white-adam-20watson-bcla-20-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:59:52</itunes:duration>
      <itunes:summary>In this discussion, Dr. Adam Watson, Co-founder and CEO of MeCo Diagnostics, shares the personal and professional experiences that led him to focus on cancer research and, ultimately, to launch his own company. From the profound influence of his family’s battle with cancer to the long and complex journey of developing the MeCo Score™, he walks us through the challenges of translating academic research into a commercial product. Dr. Watson offers insights into the realities of working with a tech transfer office, the hurdles of bringing a biomarker test to market, and the tough decision of leaving academia to pursue entrepreneurship. He also reflects on the knowledge gaps he faced as a first-time founder and the strategies that helped MeCo gain credibility in an industry dominated by large pharmaceutical companies. Finally, we discuss the broader biotech landscape—how LA’s biotech ecosystem can better support startups like MeCo, and what it will take for non–big pharma breakthroughs to gain traction in the market. Whether you&apos;re a scientist considering a leap into entrepreneurship or someone interested in the future of precision medicine, this conversation offers valuable lessons in perseverance, innovation, and the intersection of science and business.
https://mecodiagnostics.com/ 

RSVP for BCLA 10th Annual Healthcare Summit: https://lu.ma/pecqtqut</itunes:summary>
      <itunes:subtitle>In this discussion, Dr. Adam Watson, Co-founder and CEO of MeCo Diagnostics, shares the personal and professional experiences that led him to focus on cancer research and, ultimately, to launch his own company. From the profound influence of his family’s battle with cancer to the long and complex journey of developing the MeCo Score™, he walks us through the challenges of translating academic research into a commercial product. Dr. Watson offers insights into the realities of working with a tech transfer office, the hurdles of bringing a biomarker test to market, and the tough decision of leaving academia to pursue entrepreneurship. He also reflects on the knowledge gaps he faced as a first-time founder and the strategies that helped MeCo gain credibility in an industry dominated by large pharmaceutical companies. Finally, we discuss the broader biotech landscape—how LA’s biotech ecosystem can better support startups like MeCo, and what it will take for non–big pharma breakthroughs to gain traction in the market. Whether you&apos;re a scientist considering a leap into entrepreneurship or someone interested in the future of precision medicine, this conversation offers valuable lessons in perseverance, innovation, and the intersection of science and business.
https://mecodiagnostics.com/ 

RSVP for BCLA 10th Annual Healthcare Summit: https://lu.ma/pecqtqut</itunes:subtitle>
      <itunes:keywords>cancer, insidebiotech, biotech connection los angeles, biotech, startup, drug repurposing</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>28</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">46a3f43b-abe1-46b9-8310-3cfd0579c0d0</guid>
      <title>From Tech to Biotech: Lital Gilad-Shaoulian on Leading PurposeBio to Transform Cardiometabolic Health</title>
      <description><![CDATA[<p>In this episode of Inside Biotech, we sit down with Lital Gilad-Shaoulian, CEO of PurposeBio, to explore her inspiring journey from a non-science background into the world of biotech. Lital shares how she transformed PurposeBio into an industry leader focused on tackling cardiometabolic diseases. It was named by UCLA as one of its “Best and Most Investment Worthy Startups." They have been awarded the Department of Defense Award for Innovation and Impact and received a personal invitation to the annual premier pharma and healthcare conference, JPM Healthcare Conference, in San Francisco in January 2025.<br />From her early days as an Entrepreneur In Residence at Stanford Research Institute to her success as a mentor and ambassador, Lital offers powerful insights into patient-centered innovation, resilience, and team-driven leadership. She also discusses the triumphs and challenges of turning an idea into a tangible, marketable product, emphasizing the importance of persistence, collaboration, and staying focused on the end goal. Join us for an energizing conversation on purpose, innovation, and the future of biotech.</p><p>(0:00) Intro<br />(0:56) Intro to Lital Gilad Shaulian of PurposeBio for Cardiometabolic diseases<br />(2:27) Macherey-Nagel Ad<br />(3:23) Lital’s career background<br />(4:36) After Lital turned forty, she wanted a change from tech<br />(6:46) Shift from tech to biotech by reading a science article<br />(9:50) Dr. Elaine Hsiao’s research led to a collaboration towards drugs for obesity and fatty liver disease by gut microbiome<br />(13:12) Why meeting the need not focusing on the idea is important<br />(15:01) Survey of what patients with cholesterol and fatty liver disease need<br />(18:25) What are the steps of FDA approval?<br />(21:40) How Lital build her team of experts? Meeting Professor Eran Elinav and having him buy in<br />(29:03) How to get a startup off the ground and get funding?<br />(33:30) Where do the funds go currently for Purpose Bio? Science and IP<br />(35:11) What does communication look like on a day-to-day basis for Purpose Bio?<br />(36:46) The importance of thinking ahead to plan what the company needs<br />(42:22) How Lital developed her background in science by asking questions<br />(44:59) Milestones that Lital has hit with Purpose Bio and how that felt at each time<br />(49:01) The lack of control in science and not knowing what will happen when variables are manipulated<br />(50:18) What is the focus of taking the next step towards clinical trials?<br />(54:24) Purpose Bio will meet unmet needs of patients that cannot use GLP-1 or statins<br />(55:42) Side effects of statins are difficult to manage<br />(59:31) What advice would Lital give herself for the beginning of her journey?<br />(65:58) Outro</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 27 Nov 2024 23:00:00 +0000</pubDate>
      <author>team@bc-la.org (Kat Merkling, Serena Gao, Daniel Graves, Daniel Arce, Gabriella Rubert, Bryan Jimenez)</author>
      <link>https://inside-biotech.simplecast.com/episodes/from-tech-to-biotech-lital-gilad-shaoulian-on-leading-purposebio-to-transform-cardiometabolic-health-VL3lVDNQ</link>
      <content:encoded><![CDATA[<p>In this episode of Inside Biotech, we sit down with Lital Gilad-Shaoulian, CEO of PurposeBio, to explore her inspiring journey from a non-science background into the world of biotech. Lital shares how she transformed PurposeBio into an industry leader focused on tackling cardiometabolic diseases. It was named by UCLA as one of its “Best and Most Investment Worthy Startups." They have been awarded the Department of Defense Award for Innovation and Impact and received a personal invitation to the annual premier pharma and healthcare conference, JPM Healthcare Conference, in San Francisco in January 2025.<br />From her early days as an Entrepreneur In Residence at Stanford Research Institute to her success as a mentor and ambassador, Lital offers powerful insights into patient-centered innovation, resilience, and team-driven leadership. She also discusses the triumphs and challenges of turning an idea into a tangible, marketable product, emphasizing the importance of persistence, collaboration, and staying focused on the end goal. Join us for an energizing conversation on purpose, innovation, and the future of biotech.</p><p>(0:00) Intro<br />(0:56) Intro to Lital Gilad Shaulian of PurposeBio for Cardiometabolic diseases<br />(2:27) Macherey-Nagel Ad<br />(3:23) Lital’s career background<br />(4:36) After Lital turned forty, she wanted a change from tech<br />(6:46) Shift from tech to biotech by reading a science article<br />(9:50) Dr. Elaine Hsiao’s research led to a collaboration towards drugs for obesity and fatty liver disease by gut microbiome<br />(13:12) Why meeting the need not focusing on the idea is important<br />(15:01) Survey of what patients with cholesterol and fatty liver disease need<br />(18:25) What are the steps of FDA approval?<br />(21:40) How Lital build her team of experts? Meeting Professor Eran Elinav and having him buy in<br />(29:03) How to get a startup off the ground and get funding?<br />(33:30) Where do the funds go currently for Purpose Bio? Science and IP<br />(35:11) What does communication look like on a day-to-day basis for Purpose Bio?<br />(36:46) The importance of thinking ahead to plan what the company needs<br />(42:22) How Lital developed her background in science by asking questions<br />(44:59) Milestones that Lital has hit with Purpose Bio and how that felt at each time<br />(49:01) The lack of control in science and not knowing what will happen when variables are manipulated<br />(50:18) What is the focus of taking the next step towards clinical trials?<br />(54:24) Purpose Bio will meet unmet needs of patients that cannot use GLP-1 or statins<br />(55:42) Side effects of statins are difficult to manage<br />(59:31) What advice would Lital give herself for the beginning of her journey?<br />(65:58) Outro</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="64086838" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/116f979d-22ba-4268-a306-1dc795af0c9f/audio/e9292e04-5e5d-4b16-a653-5a9bce9a13ea/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>From Tech to Biotech: Lital Gilad-Shaoulian on Leading PurposeBio to Transform Cardiometabolic Health</itunes:title>
      <itunes:author>Kat Merkling, Serena Gao, Daniel Graves, Daniel Arce, Gabriella Rubert, Bryan Jimenez</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/bfdef429-38d2-41bf-8ed4-8cdbdbdea6ee/3000x3000/lital-bcla.jpg?aid=rss_feed"/>
      <itunes:duration>01:06:45</itunes:duration>
      <itunes:summary>In this episode of Inside Biotech, we sit down with Lital Gilad-Shaoulian, CEO of PurposeBio, to explore her inspiring journey from a non-science background into the world of biotech. Lital shares how she transformed PurposeBio into an industry leader focused on tackling cardiometabolic diseases. It was named by UCLA as one of its “Best and Most Investment Worthy Startups.&quot; They have been awarded the Department of Defense Award for Innovation and Impact and received a personal invitation to the annual premier pharma and healthcare conference, JPM Healthcare Conference, in San Francisco in January 2025. 
From her early days as an Entrepreneur In Residence at Stanford Research Institute to her success as a mentor and ambassador, Lital offers powerful insights into patient-centered innovation, resilience, and team-driven leadership. She also discusses the triumphs and challenges of turning an idea into a tangible, marketable product, emphasizing the importance of persistence, collaboration, and staying focused on the end goal. Join us for an energizing conversation on purpose, innovation, and the future of biotech.

(0:00) Intro
(0:56) Intro to Lital Gilad Shaulian of PurposeBio for Cardiometabolic diseases
(2:27) Macherey-Nagel Ad
(3:23) Lital’s career background
(4:36) After Lital turned forty, she wanted a change from tech
(6:46) Shift from tech to biotech by reading a science article
(9:50) Dr. Elaine Hsiao’s research led to a collaboration towards drugs for obesity and fatty liver disease by gut microbiome
(13:12) Why meeting the need not focusing on the idea is important
(15:01) Survey of what patients with cholesterol and fatty liver disease need
(18:25) What are the steps of FDA approval?
(21:40) How Lital build her team of experts? Meeting Professor Eran Elinav and having him buy in
(29:03) How to get a startup off the ground and get funding?
(33:30) Where do the funds go currently for Purpose Bio? Science and IP
(35:11) What does communication look like on a day-to-day basis for Purpose Bio?
(36:46) The importance of thinking ahead to plan what the company needs
(42:22) How Lital developed her background in science by asking questions
(44:59) Milestones that Lital has hit with Purpose Bio and how that felt at each time
(49:01) The lack of control in science and not knowing what will happen when variables are manipulated
(50:18) What is the focus of taking the next step towards clinical trials?
(54:24) Purpose Bio will meet unmet needs of patients that cannot use GLP-1 or statins
(55:42) Side effects of statins are difficult to manage
(59:31) What advice would Lital give herself for the beginning of her journey?
(65:58) Outro
</itunes:summary>
      <itunes:subtitle>In this episode of Inside Biotech, we sit down with Lital Gilad-Shaoulian, CEO of PurposeBio, to explore her inspiring journey from a non-science background into the world of biotech. Lital shares how she transformed PurposeBio into an industry leader focused on tackling cardiometabolic diseases. It was named by UCLA as one of its “Best and Most Investment Worthy Startups.&quot; They have been awarded the Department of Defense Award for Innovation and Impact and received a personal invitation to the annual premier pharma and healthcare conference, JPM Healthcare Conference, in San Francisco in January 2025. 
From her early days as an Entrepreneur In Residence at Stanford Research Institute to her success as a mentor and ambassador, Lital offers powerful insights into patient-centered innovation, resilience, and team-driven leadership. She also discusses the triumphs and challenges of turning an idea into a tangible, marketable product, emphasizing the importance of persistence, collaboration, and staying focused on the end goal. Join us for an energizing conversation on purpose, innovation, and the future of biotech.

(0:00) Intro
(0:56) Intro to Lital Gilad Shaulian of PurposeBio for Cardiometabolic diseases
(2:27) Macherey-Nagel Ad
(3:23) Lital’s career background
(4:36) After Lital turned forty, she wanted a change from tech
(6:46) Shift from tech to biotech by reading a science article
(9:50) Dr. Elaine Hsiao’s research led to a collaboration towards drugs for obesity and fatty liver disease by gut microbiome
(13:12) Why meeting the need not focusing on the idea is important
(15:01) Survey of what patients with cholesterol and fatty liver disease need
(18:25) What are the steps of FDA approval?
(21:40) How Lital build her team of experts? Meeting Professor Eran Elinav and having him buy in
(29:03) How to get a startup off the ground and get funding?
(33:30) Where do the funds go currently for Purpose Bio? Science and IP
(35:11) What does communication look like on a day-to-day basis for Purpose Bio?
(36:46) The importance of thinking ahead to plan what the company needs
(42:22) How Lital developed her background in science by asking questions
(44:59) Milestones that Lital has hit with Purpose Bio and how that felt at each time
(49:01) The lack of control in science and not knowing what will happen when variables are manipulated
(50:18) What is the focus of taking the next step towards clinical trials?
(54:24) Purpose Bio will meet unmet needs of patients that cannot use GLP-1 or statins
(55:42) Side effects of statins are difficult to manage
(59:31) What advice would Lital give herself for the beginning of her journey?
(65:58) Outro
</itunes:subtitle>
      <itunes:keywords>obesity, biotech connection los angeles, inside biotech, metabolism, biotech, career transition</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>27</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">1a3a5fc6-b3ac-4847-b04f-d0e49d9fc297</guid>
      <title>Navigating Startups and Shaping Industry Breakthroughs with Sarah Ives from TripleBar</title>
      <description><![CDATA[<p>In this episode, we follow the inspiring journey of Sarah Ives, Vice President of BioPharma at TripleBar, as she shares her transition from a hands-on scientist to an influential leader in biotech. Sarah shares her journey, starting with her early work in bioassay development and biosensing, and candidly discusses the challenges she faced as she moved beyond the lab bench. Her growing expertise played a pivotal role in driving some of her company’s most important breakthroughs. She reveals the unexpected twists, personal growth, and strategic decisions that helped shape her career. Sarah’s candid reflection on navigating the biotech startup world, embracing uncertainty, and finding her passion for biology provides invaluable insights for anyone aspiring to make their mark in the field. Whether you're new to biotech or aiming for leadership, this episode is packed with practical advice and inspiration, this episode is a must-listen for anyone looking to make their mark in the field.</p><p>(0:00) Intro<br />(0:55) Sarah Ives feature and background<br />(2:15) Macherey-Nagel Ad<br />(3:11) Welcome Sarah Ives VP of Triple bar, how her professional journey led to this point<br />(4:45) How was Sarah’s first transition from a masters to industry and why University of San Francisco<br />(8:34) What is the difference between an internship and a full-time position?<br />(11:10) Sarah started early in her career with client management and staying organized with science<br />(12:11) Was there always a draw to a people facing role?<br />(15:00) How to transition from pharma to startups? Connections.<br />(18:20) Anecdote from how different the startup world is?<br />(21:00) The first biotech company Sarah worked for was bootstrapped<br />(22:45) Startups need to keep funding to grow! Sarah wore many hats working for first company.<br />(27:00) Importance to learn and advocate for yourself in science<br />(31:22) Transition as Distributed Bio startup was sold to Charles River<br />(34:40) Sarah was tired after her time working at a startup and transition to Charles River<br />(37:20) Sarah Ives had consulting projects trickle in from how she was highly visible as an expert in antibody engineering<br />(41:05) Time off caused Sarah to learn a lot about herself and resiliency and persistence<br />(43:12) How was the work on the universal flu vaccine that led to Sarah being featured on a Netflix documentary?<br />(46:22) Sarah and others in the Netflix documentary were predicting concern for a respiratory virus right before the pandemic<br />(49:22) Sarah was so happy with all the nice feedback she got from the pandemic<br />(51:22) Advice for those looking to get into the startup world?<br />(54:40) Outro</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 16 Oct 2024 14:00:00 +0000</pubDate>
      <author>team@bc-la.org (Bryan Jimenez, Daniel Graves, Kat Merkling, Serena Gao, Daniel Arce, Gabriella Rubert, Carys Layton)</author>
      <link>https://inside-biotech.simplecast.com/episodes/navigating-startups-and-shaping-industry-breakthroughs-with-sarah-ives-from-triplebar-UHjOjEn8</link>
      <content:encoded><![CDATA[<p>In this episode, we follow the inspiring journey of Sarah Ives, Vice President of BioPharma at TripleBar, as she shares her transition from a hands-on scientist to an influential leader in biotech. Sarah shares her journey, starting with her early work in bioassay development and biosensing, and candidly discusses the challenges she faced as she moved beyond the lab bench. Her growing expertise played a pivotal role in driving some of her company’s most important breakthroughs. She reveals the unexpected twists, personal growth, and strategic decisions that helped shape her career. Sarah’s candid reflection on navigating the biotech startup world, embracing uncertainty, and finding her passion for biology provides invaluable insights for anyone aspiring to make their mark in the field. Whether you're new to biotech or aiming for leadership, this episode is packed with practical advice and inspiration, this episode is a must-listen for anyone looking to make their mark in the field.</p><p>(0:00) Intro<br />(0:55) Sarah Ives feature and background<br />(2:15) Macherey-Nagel Ad<br />(3:11) Welcome Sarah Ives VP of Triple bar, how her professional journey led to this point<br />(4:45) How was Sarah’s first transition from a masters to industry and why University of San Francisco<br />(8:34) What is the difference between an internship and a full-time position?<br />(11:10) Sarah started early in her career with client management and staying organized with science<br />(12:11) Was there always a draw to a people facing role?<br />(15:00) How to transition from pharma to startups? Connections.<br />(18:20) Anecdote from how different the startup world is?<br />(21:00) The first biotech company Sarah worked for was bootstrapped<br />(22:45) Startups need to keep funding to grow! Sarah wore many hats working for first company.<br />(27:00) Importance to learn and advocate for yourself in science<br />(31:22) Transition as Distributed Bio startup was sold to Charles River<br />(34:40) Sarah was tired after her time working at a startup and transition to Charles River<br />(37:20) Sarah Ives had consulting projects trickle in from how she was highly visible as an expert in antibody engineering<br />(41:05) Time off caused Sarah to learn a lot about herself and resiliency and persistence<br />(43:12) How was the work on the universal flu vaccine that led to Sarah being featured on a Netflix documentary?<br />(46:22) Sarah and others in the Netflix documentary were predicting concern for a respiratory virus right before the pandemic<br />(49:22) Sarah was so happy with all the nice feedback she got from the pandemic<br />(51:22) Advice for those looking to get into the startup world?<br />(54:40) Outro</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="53696377" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/7ea22718-3fc4-45e2-bf8b-bcb839edc6bb/audio/46059e4b-d0c7-4e32-8546-9eda62f54069/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Navigating Startups and Shaping Industry Breakthroughs with Sarah Ives from TripleBar</itunes:title>
      <itunes:author>Bryan Jimenez, Daniel Graves, Kat Merkling, Serena Gao, Daniel Arce, Gabriella Rubert, Carys Layton</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/0c3e2f87-f985-4551-95b7-22dd0774bec9/3000x3000/sarah-20ives-bcla.jpg?aid=rss_feed"/>
      <itunes:duration>00:55:55</itunes:duration>
      <itunes:summary>In this episode, we follow the inspiring journey of Sarah Ives, Vice President of BioPharma at TripleBar, as she shares her transition from a hands-on scientist to an influential leader in biotech. Sarah shares her journey, starting with her early work in bioassay development and biosensing, and candidly discusses the challenges she faced as she moved beyond the lab bench. Her growing expertise played a pivotal role in driving some of her company’s most important breakthroughs. She reveals the unexpected twists, personal growth, and strategic decisions that helped shape her career. Sarah’s candid reflection on navigating the biotech startup world, embracing uncertainty, and finding her passion for biology provides invaluable insights for anyone aspiring to make their mark in the field. Whether you&apos;re new to biotech or aiming for leadership, this episode is packed with practical advice and inspiration, this episode is a must-listen for anyone looking to make their mark in the field.

(0:00) Intro
(0:55) Sarah Ives feature and background
(2:15) Macherey-Nagel Ad
(3:11) Welcome Sarah Ives VP of Triple bar, how her professional journey led to this point
(4:45) How was Sarah’s first transition from a masters to industry and why University of San Francisco
(8:34) What is the difference between an internship and a full-time position?
(11:10) Sarah started early in her career with client management and staying organized with science
(12:11) Was there always a draw to a people facing role?
(15:00) How to transition from pharma to startups? Connections.
(18:20) Anecdote from how different the startup world is?
(21:00) The first biotech company Sarah worked for was bootstrapped
(22:45) Startups need to keep funding to grow! Sarah wore many hats working for first company.
(27:00) Importance to learn and advocate for yourself in science
(31:22) Transition as Distributed Bio startup was sold to Charles River
(34:40) Sarah was tired after her time working at a startup and transition to Charles River
(37:20) Sarah Ives had consulting projects trickle in from how she was highly visible as an expert in antibody engineering
(41:05) Time off caused Sarah to learn a lot about herself and resiliency and persistence
(43:12) How was the work on the universal flu vaccine that led to Sarah being featured on a Netflix documentary?
(46:22) Sarah and others in the Netflix documentary were predicting concern for a respiratory virus right before the pandemic
(49:22) Sarah was so happy with all the nice feedback she got from the pandemic
(51:22) Advice for those looking to get into the startup world?
(54:40) Outro
</itunes:summary>
      <itunes:subtitle>In this episode, we follow the inspiring journey of Sarah Ives, Vice President of BioPharma at TripleBar, as she shares her transition from a hands-on scientist to an influential leader in biotech. Sarah shares her journey, starting with her early work in bioassay development and biosensing, and candidly discusses the challenges she faced as she moved beyond the lab bench. Her growing expertise played a pivotal role in driving some of her company’s most important breakthroughs. She reveals the unexpected twists, personal growth, and strategic decisions that helped shape her career. Sarah’s candid reflection on navigating the biotech startup world, embracing uncertainty, and finding her passion for biology provides invaluable insights for anyone aspiring to make their mark in the field. Whether you&apos;re new to biotech or aiming for leadership, this episode is packed with practical advice and inspiration, this episode is a must-listen for anyone looking to make their mark in the field.

(0:00) Intro
(0:55) Sarah Ives feature and background
(2:15) Macherey-Nagel Ad
(3:11) Welcome Sarah Ives VP of Triple bar, how her professional journey led to this point
(4:45) How was Sarah’s first transition from a masters to industry and why University of San Francisco
(8:34) What is the difference between an internship and a full-time position?
(11:10) Sarah started early in her career with client management and staying organized with science
(12:11) Was there always a draw to a people facing role?
(15:00) How to transition from pharma to startups? Connections.
(18:20) Anecdote from how different the startup world is?
(21:00) The first biotech company Sarah worked for was bootstrapped
(22:45) Startups need to keep funding to grow! Sarah wore many hats working for first company.
(27:00) Importance to learn and advocate for yourself in science
(31:22) Transition as Distributed Bio startup was sold to Charles River
(34:40) Sarah was tired after her time working at a startup and transition to Charles River
(37:20) Sarah Ives had consulting projects trickle in from how she was highly visible as an expert in antibody engineering
(41:05) Time off caused Sarah to learn a lot about herself and resiliency and persistence
(43:12) How was the work on the universal flu vaccine that led to Sarah being featured on a Netflix documentary?
(46:22) Sarah and others in the Netflix documentary were predicting concern for a respiratory virus right before the pandemic
(49:22) Sarah was so happy with all the nice feedback she got from the pandemic
(51:22) Advice for those looking to get into the startup world?
(54:40) Outro
</itunes:subtitle>
      <itunes:keywords>careers, biotech connection los angeles, inside biotech, consulting, biotech, career transition, pharma, startup</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>26</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f6e09f89-2874-422f-83a7-047b4b455956</guid>
      <title>Career Pivot to Biotech Product Management with Sara Tafoya from Sony Biotechnology</title>
      <description><![CDATA[<p>In this episode of Inside Biotech, we explore the transition from academia to product management with Dr. Sara Tafoya, Global Product Manager at Sony Biotechnology. Sara’s passion lies in helping STEM graduate students and early career professionals recognize the value of their technical expertise beyond the bench. She shares her journey from PhD to product management, discussing how she bridges technical know-how with customer advocacy and sales to drive innovation in biotech. If you've ever wondered how to apply your niche academic skills to roles outside of research, this episode is packed with actionable insights. Listen in as Sara offers advice on professional development and how to pursue fulfilling, impactful careers that push scientific innovation forward.</p><p>(0:00) Intro<br />(1:01) Episode summary overview with Dr. Sara Tafoya - Product management.<br />(2:07) Salve Therapeutics Ad.<br />(2:47) Sara Tafoya wants to share knowledge and help future scientist with career transitions<br />(4:35) Sara discusses her rationale to be on the podcast.<br />(5:57) Questions of the episode: What does a day in the life as a product manager look like? How to know that this career might be a good fit for you and then how to get involved in this career?<br />(6:39) What products does Sara Tafoya manage for Sony Biotechnology?<br />(7:40) Sony Biotechnology makes technology for flow cytometry<br />(9:30) What is flow cytometry?<br />(11:55) Huge development in flow cytometry to use many different fluorophores in one sample<br />(14:21) New developments in microfluidic chips<br />(15:57) What characteristics make a good product manager in science apart from great communication?<br />(16:54) Great people skills are a must for product managers<br />(18:00) Two different jobs in product management, helping the customer and then helping the company with ideas and improvements<br />(19:40) When being a product manager focus on customer segments (Academia vs. Industry) focus on affordability vs. capability<br />(21:20) Product managers need to go out and find needs of company. What consumers care about in improvements<br />(22:46) Do you travel and how is work life balance as a product manager?<br />(24:32) Traveling depends on what you are doing but no substitute for being exposed in person.<br />(25:05) Salve Therapeutics Ad<br />(25:45) What drove Dr. Tafoya to this career path? 27:10 -27:50<br />(27:50) How did the skills Sara picked up in her PhD help with product management and what did she need to learn afterwards?<br />(30:00) You will always need to understand commercial space and biotech ecosystem once you start your career in industry?<br />(30:40) What surprised Sara about being a product manager?<br />(33:05) Sara took a course in product management from Warton to help with business side<br />(35:40) What skills are translatable from scientific expertise to product management?<br />(38:30) Importance of using scientific reasoning and thinking on the job<br />(39:48) How to break into the world of product management?<br />(41:27) You typically need to pay your dues to get a role in product management<br />(45:30) Try to figure out what career you want so less sacrifices are made later on or you can get lucky.<br />(47:00) Ad for Macherey-Nagle<br />(47:52) What is next for Sara in her career?<br />(50:04) Sara wants to create a great team with effective communication and change the way things are done at work<br />(51:51) What are Sara’s hobbies?<br />(55:20) Episode wrap up</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 18 Sep 2024 14:00:00 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Daniel Arce, Kat Merkling, Serena Gao, Carys Layton, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/career-pivot-to-biotech-product-management-with-sara-tafoya-from-sony-biotechnology-lKJPr7nI</link>
      <content:encoded><![CDATA[<p>In this episode of Inside Biotech, we explore the transition from academia to product management with Dr. Sara Tafoya, Global Product Manager at Sony Biotechnology. Sara’s passion lies in helping STEM graduate students and early career professionals recognize the value of their technical expertise beyond the bench. She shares her journey from PhD to product management, discussing how she bridges technical know-how with customer advocacy and sales to drive innovation in biotech. If you've ever wondered how to apply your niche academic skills to roles outside of research, this episode is packed with actionable insights. Listen in as Sara offers advice on professional development and how to pursue fulfilling, impactful careers that push scientific innovation forward.</p><p>(0:00) Intro<br />(1:01) Episode summary overview with Dr. Sara Tafoya - Product management.<br />(2:07) Salve Therapeutics Ad.<br />(2:47) Sara Tafoya wants to share knowledge and help future scientist with career transitions<br />(4:35) Sara discusses her rationale to be on the podcast.<br />(5:57) Questions of the episode: What does a day in the life as a product manager look like? How to know that this career might be a good fit for you and then how to get involved in this career?<br />(6:39) What products does Sara Tafoya manage for Sony Biotechnology?<br />(7:40) Sony Biotechnology makes technology for flow cytometry<br />(9:30) What is flow cytometry?<br />(11:55) Huge development in flow cytometry to use many different fluorophores in one sample<br />(14:21) New developments in microfluidic chips<br />(15:57) What characteristics make a good product manager in science apart from great communication?<br />(16:54) Great people skills are a must for product managers<br />(18:00) Two different jobs in product management, helping the customer and then helping the company with ideas and improvements<br />(19:40) When being a product manager focus on customer segments (Academia vs. Industry) focus on affordability vs. capability<br />(21:20) Product managers need to go out and find needs of company. What consumers care about in improvements<br />(22:46) Do you travel and how is work life balance as a product manager?<br />(24:32) Traveling depends on what you are doing but no substitute for being exposed in person.<br />(25:05) Salve Therapeutics Ad<br />(25:45) What drove Dr. Tafoya to this career path? 27:10 -27:50<br />(27:50) How did the skills Sara picked up in her PhD help with product management and what did she need to learn afterwards?<br />(30:00) You will always need to understand commercial space and biotech ecosystem once you start your career in industry?<br />(30:40) What surprised Sara about being a product manager?<br />(33:05) Sara took a course in product management from Warton to help with business side<br />(35:40) What skills are translatable from scientific expertise to product management?<br />(38:30) Importance of using scientific reasoning and thinking on the job<br />(39:48) How to break into the world of product management?<br />(41:27) You typically need to pay your dues to get a role in product management<br />(45:30) Try to figure out what career you want so less sacrifices are made later on or you can get lucky.<br />(47:00) Ad for Macherey-Nagle<br />(47:52) What is next for Sara in her career?<br />(50:04) Sara wants to create a great team with effective communication and change the way things are done at work<br />(51:51) What are Sara’s hobbies?<br />(55:20) Episode wrap up</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="54906369" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/f1bad691-5684-4147-951f-37490fc90e58/audio/5fc29360-5225-462a-92da-f2ee945a644f/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Career Pivot to Biotech Product Management with Sara Tafoya from Sony Biotechnology</itunes:title>
      <itunes:author>Gabriella Rubert, Daniel Arce, Kat Merkling, Serena Gao, Carys Layton, Daniel Graves</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/3a680315-3a5a-45e3-9668-bea0f0517bb6/3000x3000/sara-20tafoya-20-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:57:11</itunes:duration>
      <itunes:summary>In this episode of Inside Biotech, we explore the transition from academia to product management with Dr. Sara Tafoya, Global Product Manager at Sony Biotechnology. Sara’s passion lies in helping STEM graduate students and early career professionals recognize the value of their technical expertise beyond the bench. She shares her journey from PhD to product management, discussing how she bridges technical know-how with customer advocacy and sales to drive innovation in biotech. If you&apos;ve ever wondered how to apply your niche academic skills to roles outside of research, this episode is packed with actionable insights. Listen in as Sara offers advice on professional development and how to pursue fulfilling, impactful careers that push scientific innovation forward.</itunes:summary>
      <itunes:subtitle>In this episode of Inside Biotech, we explore the transition from academia to product management with Dr. Sara Tafoya, Global Product Manager at Sony Biotechnology. Sara’s passion lies in helping STEM graduate students and early career professionals recognize the value of their technical expertise beyond the bench. She shares her journey from PhD to product management, discussing how she bridges technical know-how with customer advocacy and sales to drive innovation in biotech. If you&apos;ve ever wondered how to apply your niche academic skills to roles outside of research, this episode is packed with actionable insights. Listen in as Sara offers advice on professional development and how to pursue fulfilling, impactful careers that push scientific innovation forward.</itunes:subtitle>
      <itunes:keywords>careers, biotech connection los angeles, inside biotech, biotech, product management</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>25</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f534ec88-afa0-49e1-9cf1-b5895e0fb804</guid>
      <title>Special Feature - Pursuing Life Sciences Careers: Insights from Anderson MBA Students</title>
      <description><![CDATA[<p>Considering an MBA at UCLA Anderson? Hear from current MBA students. </p><p>Our episode today features coverage of a past collaborative event held by BCLA and UCLA Anderson “Pursuing Life Sciences Careers: Insights from Anderson MBA Students.” This event included a panel of current Anderson MBA students working in Life Sciences. Panelists included Arthela Osorio (Technical Training Manager at Thermo Fisher Scientific), Chris Italiaie ( Engineering Program Manager at Medtronic), Lauren Chan (Sr. Global Program Manager at Amgen), Angel Torres (Assistant CAPEX Program Manager at Genetech), and Purvi Mehram, MD (CEO of Dagnee).</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">https://www.bc-la.org/</a><br />To learn more about UCLA Anderson School of Management visit <a href="https://www.anderson.ucla.edu/">https://www.anderson.ucla.edu/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 19 Jun 2024 15:00:00 +0000</pubDate>
      <author>team@bc-la.org (Dana Franklin, Jennifer Olivero, Serena Gao, Daniel Arce, Gabriella Rubert, Kat Merkling, Carys Layton)</author>
      <link>https://inside-biotech.simplecast.com/episodes/bcla-edition-audio-uploaded-c1AGjZZG</link>
      <content:encoded><![CDATA[<p>Considering an MBA at UCLA Anderson? Hear from current MBA students. </p><p>Our episode today features coverage of a past collaborative event held by BCLA and UCLA Anderson “Pursuing Life Sciences Careers: Insights from Anderson MBA Students.” This event included a panel of current Anderson MBA students working in Life Sciences. Panelists included Arthela Osorio (Technical Training Manager at Thermo Fisher Scientific), Chris Italiaie ( Engineering Program Manager at Medtronic), Lauren Chan (Sr. Global Program Manager at Amgen), Angel Torres (Assistant CAPEX Program Manager at Genetech), and Purvi Mehram, MD (CEO of Dagnee).</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">https://www.bc-la.org/</a><br />To learn more about UCLA Anderson School of Management visit <a href="https://www.anderson.ucla.edu/">https://www.anderson.ucla.edu/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="48120383" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/56eb1b4d-6f15-46ec-aadf-25bf79031603/audio/765b577d-ebbb-4f18-9623-57d8bbee391f/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Special Feature - Pursuing Life Sciences Careers: Insights from Anderson MBA Students</itunes:title>
      <itunes:author>Dana Franklin, Jennifer Olivero, Serena Gao, Daniel Arce, Gabriella Rubert, Kat Merkling, Carys Layton</itunes:author>
      <itunes:duration>00:50:07</itunes:duration>
      <itunes:summary>Considering an MBA at UCLA Anderson? Hear from current MBA students. </itunes:summary>
      <itunes:subtitle>Considering an MBA at UCLA Anderson? Hear from current MBA students. </itunes:subtitle>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>24</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">9e9ca552-f4aa-47a8-9aba-1bfc5c23cf7f</guid>
      <title>Where Biotech Meets the Business: Proteomics Product Management with Ivan Godinez from Proteintech</title>
      <description><![CDATA[<p>Dr. Ivan Godinez is the Director of Product Management for the Proteintech genomics division. Ivan describes how his work translates the latest developments in proteomics and genomics to accessible biotechnology for consumers. Dr. Godinez relates the importance of his training as a PhD scientist and valuable soft skills developed to be a successful director of product management. </p><p>(2:00) What does Ivan do for Proteintech?<br />(4:10) Importance of single-cell level resolution and getting diverse data to answer scientific questions with different approaches<br />(6:10) How did Ivan get to where he wanted? <br />(8:12) Ivan's entrance into biotech, and subsequently, product management.<br />(13:30) What makes a great product manager?<br />(22:07) The science behind Proteintech<br />(34:57)  Proteomics compared to transcriptomics (RNA-seq) and the unique challenges of proteomics. <br />(38:35) Advice to students regarding taking the leap from benchtop science to business in biotechnology companies.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 17 Apr 2024 18:31:29 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Carys Layton, Serena Gao, Daniel Arce, Katherine Merkling, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/where-biotech-meets-the-business-product-management-with-ivan-godinez-proteintech-cYTQSPgZ</link>
      <content:encoded><![CDATA[<p>Dr. Ivan Godinez is the Director of Product Management for the Proteintech genomics division. Ivan describes how his work translates the latest developments in proteomics and genomics to accessible biotechnology for consumers. Dr. Godinez relates the importance of his training as a PhD scientist and valuable soft skills developed to be a successful director of product management. </p><p>(2:00) What does Ivan do for Proteintech?<br />(4:10) Importance of single-cell level resolution and getting diverse data to answer scientific questions with different approaches<br />(6:10) How did Ivan get to where he wanted? <br />(8:12) Ivan's entrance into biotech, and subsequently, product management.<br />(13:30) What makes a great product manager?<br />(22:07) The science behind Proteintech<br />(34:57)  Proteomics compared to transcriptomics (RNA-seq) and the unique challenges of proteomics. <br />(38:35) Advice to students regarding taking the leap from benchtop science to business in biotechnology companies.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="45083910" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/617efcec-46f1-447b-813b-801182c0d4b0/audio/566172d9-91f9-4a09-b24c-730c9755607b/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Where Biotech Meets the Business: Proteomics Product Management with Ivan Godinez from Proteintech</itunes:title>
      <itunes:author>Gabriella Rubert, Carys Layton, Serena Gao, Daniel Arce, Katherine Merkling, Daniel Graves</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/bdb528e7-cefe-4f05-9664-8e04641e6090/3000x3000/ivan-podcast-flier.jpg?aid=rss_feed"/>
      <itunes:duration>00:46:57</itunes:duration>
      <itunes:summary>Dr. Ivan Godinez is the Director of Product Management for the Proteintech genomics division. Ivan describes how his work translates the latest developments in proteomics and genomics to accessible biotechnology for consumers. Dr. Godinez relates the importance of his training as a PhD scientist and valuable soft skills developed to be a successful director of product management. </itunes:summary>
      <itunes:subtitle>Dr. Ivan Godinez is the Director of Product Management for the Proteintech genomics division. Ivan describes how his work translates the latest developments in proteomics and genomics to accessible biotechnology for consumers. Dr. Godinez relates the importance of his training as a PhD scientist and valuable soft skills developed to be a successful director of product management. </itunes:subtitle>
      <itunes:keywords>proteomics, biotech, multiomics, product management</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>23</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">17d9b25b-fa8e-4290-8ac2-7f42fa313aca</guid>
      <title>Navigating Career Transitions in Biotech - Next Generation Sequencing (NGS) Edition with Joyee Yao from Complete Genomics</title>
      <description><![CDATA[<p>Join a conversation about different types of roles in biotech, through the experience of Joyee Yao, a next-generation sequencing specialist, at Complete Genomics. After joining a research lab as an undergrad volunteer, Joy decided to join the next-generation sequencing (NGS) space as a technical specialist before pivoting into the sales space.</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">https://www.bc-la.org/</a></p><p>Complete Genomics: <a href="https://www.completegenomics.com/company/about-us/">https://www.completegenomics.com/company/about-us/</a></p><p>Joyee Yao’s LinkedIn: <a href="https://www.linkedin.com/in/joyee-yao-74901212/">https://www.linkedin.com/in/joyee-yao-74901212/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 20 Mar 2024 15:00:00 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Carys Layton, Serena Gao, Katherine Merkling, Daniel Graves, Daniel Arce)</author>
      <link>https://inside-biotech.simplecast.com/episodes/navigating-career-transitions-in-biotech-next-generation-sequencing-ngs-edition-with-joyee-yao-from-complete-genomics-N3Xsx6LK</link>
      <content:encoded><![CDATA[<p>Join a conversation about different types of roles in biotech, through the experience of Joyee Yao, a next-generation sequencing specialist, at Complete Genomics. After joining a research lab as an undergrad volunteer, Joy decided to join the next-generation sequencing (NGS) space as a technical specialist before pivoting into the sales space.</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">https://www.bc-la.org/</a></p><p>Complete Genomics: <a href="https://www.completegenomics.com/company/about-us/">https://www.completegenomics.com/company/about-us/</a></p><p>Joyee Yao’s LinkedIn: <a href="https://www.linkedin.com/in/joyee-yao-74901212/">https://www.linkedin.com/in/joyee-yao-74901212/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="44322806" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/fa1d4214-85f7-49da-8d90-13bb6eebae47/audio/231df067-63b4-4cc0-ad3d-842fee06a2d1/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Navigating Career Transitions in Biotech - Next Generation Sequencing (NGS) Edition with Joyee Yao from Complete Genomics</itunes:title>
      <itunes:author>Gabriella Rubert, Carys Layton, Serena Gao, Katherine Merkling, Daniel Graves, Daniel Arce</itunes:author>
      <itunes:duration>00:46:10</itunes:duration>
      <itunes:summary>Join a conversation about different types of roles in biotech, through the experience of Joyee Yao, a next-generation sequencing specialist, at Complete Genomics. After joining a research lab as an undergrad volunteer, Joy decided to join the next-generation sequencing (NGS) space as a technical specialist before pivoting into the sales space.

What is NGS? Previously termed massively parallel sequencing, NGS technology can identify the sequence of DNA or RNA for MANY strands at once instead of simply one strand at a time. This means, scientists can use NGS to exame sequences of thousands of genes at once to try and identify which one could contain a mutation that could be making a person sick. NGS technology isn’t limited to just DNA sequencing; this high-throughput technology can also be used to  quantify mRNA. mRNA is what is translated into proteins; for many genes, the amount of mRNA made from a gene correlates to the amount of protein made from that same gene. Just like that, we have access to massive amounts of data that can tell us about our genes, and the implications held in the proteins they encode.

Almost twenty years since the commercialization of NGS technology, we are continuing to see novel developments and improvements in the applications of NGS - ChIP-seq, Single-nucleus sequencing, spatial transcriptomics to name a few. And today, I am excited to talk to Joyee Yao, sequencing solution specialist at Complete Genomics, about her experience working in the NGS industry space over the past decade. </itunes:summary>
      <itunes:subtitle>Join a conversation about different types of roles in biotech, through the experience of Joyee Yao, a next-generation sequencing specialist, at Complete Genomics. After joining a research lab as an undergrad volunteer, Joy decided to join the next-generation sequencing (NGS) space as a technical specialist before pivoting into the sales space.

What is NGS? Previously termed massively parallel sequencing, NGS technology can identify the sequence of DNA or RNA for MANY strands at once instead of simply one strand at a time. This means, scientists can use NGS to exame sequences of thousands of genes at once to try and identify which one could contain a mutation that could be making a person sick. NGS technology isn’t limited to just DNA sequencing; this high-throughput technology can also be used to  quantify mRNA. mRNA is what is translated into proteins; for many genes, the amount of mRNA made from a gene correlates to the amount of protein made from that same gene. Just like that, we have access to massive amounts of data that can tell us about our genes, and the implications held in the proteins they encode.

Almost twenty years since the commercialization of NGS technology, we are continuing to see novel developments and improvements in the applications of NGS - ChIP-seq, Single-nucleus sequencing, spatial transcriptomics to name a few. And today, I am excited to talk to Joyee Yao, sequencing solution specialist at Complete Genomics, about her experience working in the NGS industry space over the past decade. </itunes:subtitle>
      <itunes:keywords>sequencing, biotech sales, insidebiotech, biotech connection los angeles</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>22</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">9438686e-40b8-4e08-9b63-ffc51bb93027</guid>
      <title>Innovation in Inclusive Beauty Product Development - AJ Addae, SULA LABS</title>
      <description><![CDATA[<p>This month's episode is all about biotech product development outside of healthcare in the consumer market of skincare and beauty with the overall goal of expanding diversity and inclusivity. Gabriella had a chance to sit down with AJ Addae, Founder and Formulation Chemist at SULA LABS, which is a research and development company known for providing product development expertise, clinical testing, and laboratory resources to independent companies in the skincare and beauty market. Their partnerships consist of Black Indigenous People of Color (BIPOC), nonbinary, and women-owned independent businesses, and their clientele have affiliations with Sephora, Unilever, Target, Credo, and Ulta. Listen in to hear all about AJ's inspiring work transforming the approach to product development to foster inclusivity in a consumer market centered around our largest organ - skin! </p><p>To learn more about SULA LABS visit <a href="https://www.sula-labs.com/">https://www.sula-labs.com/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 21 Feb 2024 16:00:00 +0000</pubDate>
      <author>team@bc-la.org (Katherine Merkling, Carys Layton, Gabriella Rubert, Daniel Arce, Daniel Graves, Serena Gao)</author>
      <link>https://inside-biotech.simplecast.com/episodes/innovation-in-inclusive-beauty-product-development-BhR9KhJ4</link>
      <content:encoded><![CDATA[<p>This month's episode is all about biotech product development outside of healthcare in the consumer market of skincare and beauty with the overall goal of expanding diversity and inclusivity. Gabriella had a chance to sit down with AJ Addae, Founder and Formulation Chemist at SULA LABS, which is a research and development company known for providing product development expertise, clinical testing, and laboratory resources to independent companies in the skincare and beauty market. Their partnerships consist of Black Indigenous People of Color (BIPOC), nonbinary, and women-owned independent businesses, and their clientele have affiliations with Sephora, Unilever, Target, Credo, and Ulta. Listen in to hear all about AJ's inspiring work transforming the approach to product development to foster inclusivity in a consumer market centered around our largest organ - skin! </p><p>To learn more about SULA LABS visit <a href="https://www.sula-labs.com/">https://www.sula-labs.com/</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="45250258" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/ae8542cf-2346-4f04-8675-ecb66686e882/audio/54422033-9949-439f-b828-de1a894dfd94/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Innovation in Inclusive Beauty Product Development - AJ Addae, SULA LABS</itunes:title>
      <itunes:author>Katherine Merkling, Carys Layton, Gabriella Rubert, Daniel Arce, Daniel Graves, Serena Gao</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/4cde4ba7-1f1f-4646-b5d5-8bbd5dfedf35/3000x3000/aj-flier-border.jpg?aid=rss_feed"/>
      <itunes:duration>00:47:08</itunes:duration>
      <itunes:summary>This month&apos;s episode is all about biotech product development outside of healthcare in the consumer market of skincare and beauty with the overall goal of expanding diversity and inclusivity. Gabriella had a chance to sit down with AJ Addae, Founder and Formulation Chemist at SULA LABS, which is a research and development company known for providing product development expertise, clinical testing, and laboratory resources to independent companies in the skincare and beauty market. Their partnerships consist of Black Indigenous People of Color (BIPOC), nonbinary, and women-owned independent businesses, and their clientele have affiliations with Sephora, Unilever, Target, Credo, and Ulta. Listen in to hear all about AJ&apos;s inspiring work transforming the approach to product development to foster inclusivity in a consumer market centered around our largest organ - skin! </itunes:summary>
      <itunes:subtitle>This month&apos;s episode is all about biotech product development outside of healthcare in the consumer market of skincare and beauty with the overall goal of expanding diversity and inclusivity. Gabriella had a chance to sit down with AJ Addae, Founder and Formulation Chemist at SULA LABS, which is a research and development company known for providing product development expertise, clinical testing, and laboratory resources to independent companies in the skincare and beauty market. Their partnerships consist of Black Indigenous People of Color (BIPOC), nonbinary, and women-owned independent businesses, and their clientele have affiliations with Sephora, Unilever, Target, Credo, and Ulta. Listen in to hear all about AJ&apos;s inspiring work transforming the approach to product development to foster inclusivity in a consumer market centered around our largest organ - skin! </itunes:subtitle>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>21</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f622130e-e12d-4052-a753-b8027a8e8a36</guid>
      <title>AI’s Insight into Cerebral Blood Flow with Robert Hamilton, CEO/co-Founder of NeuraSignal</title>
      <description><![CDATA[<p>NeuraSignal:</p><p><a href="https://www.neurasignal.com">https://www.neurasignal.com</a></p><p><a href="https://www.linkedin.com/company/neurasignal/">https://www.linkedin.com/company/neurasignal/</a></p><p>Robert Hamilton: </p><p>https://www.linkedin.com/in/hamiltonrobert/</p><p>To learn more about BCLA and our events, check out: </p><p><a href="https://www.bc-la.org/">https://www.bc-la.org</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 17 Jan 2024 16:00:00 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Daniel Arce, Kat Merkling, Serena Gao, Carys Layton, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/robert-hamilton-T5J4cOXn</link>
      <content:encoded><![CDATA[<p>NeuraSignal:</p><p><a href="https://www.neurasignal.com">https://www.neurasignal.com</a></p><p><a href="https://www.linkedin.com/company/neurasignal/">https://www.linkedin.com/company/neurasignal/</a></p><p>Robert Hamilton: </p><p>https://www.linkedin.com/in/hamiltonrobert/</p><p>To learn more about BCLA and our events, check out: </p><p><a href="https://www.bc-la.org/">https://www.bc-la.org</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="43944971" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/696c12eb-068d-4882-93a7-f07936a4c63c/audio/9e9d3171-b0c2-467b-8bd8-121c30057388/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>AI’s Insight into Cerebral Blood Flow with Robert Hamilton, CEO/co-Founder of NeuraSignal</itunes:title>
      <itunes:author>Gabriella Rubert, Daniel Arce, Kat Merkling, Serena Gao, Carys Layton, Daniel Graves</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/fafc836b-7d6d-4c18-8492-bbcfd776a02f/3000x3000/robhamiltonbcla.jpg?aid=rss_feed"/>
      <itunes:duration>00:45:46</itunes:duration>
      <itunes:summary>Artificial intelligence has become an integral part of contemporary society, permeating facets of daily life including art, business, and even cars. Perhaps one of the most exciting fronts on which AI is pioneering progress is in the hospital. Inside Biotech host Gabriella gets a chance to sit down and talk to the CEO of a NeuraSignal, a company that’s been committed to improving healthcare diagnostics for brain diseases by infusing existing med-tech with AI for a decade. </itunes:summary>
      <itunes:subtitle>Artificial intelligence has become an integral part of contemporary society, permeating facets of daily life including art, business, and even cars. Perhaps one of the most exciting fronts on which AI is pioneering progress is in the hospital. Inside Biotech host Gabriella gets a chance to sit down and talk to the CEO of a NeuraSignal, a company that’s been committed to improving healthcare diagnostics for brain diseases by infusing existing med-tech with AI for a decade. </itunes:subtitle>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>20</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5964f7be-4da2-494f-9c58-7430e23ca74a</guid>
      <title>Angelita de la Luz, Global Director of Pollination Operations at Beeflow</title>
      <description><![CDATA[<p>Angie de la Luz: https://www.linkedin.com/in/angelita-de-la-luz-phd-a2a937168/</p><p>Beeflow: https://www.beeflow.com/</p><p>To learn more about BCLA and our events, check out: </p><p><a href="https://www.bc-la.org/">https://www.bc-la.org</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 15 Nov 2023 15:00:00 +0000</pubDate>
      <author>team@bc-la.org (Kat Merkling, Gabriella Rubert, Daniel Graves, Daniel Arce)</author>
      <link>https://inside-biotech.simplecast.com/episodes/angelita-de-la-luz-global-director-of-pollination-operations-at-beeflow-d_rFDnWd</link>
      <content:encoded><![CDATA[<p>Angie de la Luz: https://www.linkedin.com/in/angelita-de-la-luz-phd-a2a937168/</p><p>Beeflow: https://www.beeflow.com/</p><p>To learn more about BCLA and our events, check out: </p><p><a href="https://www.bc-la.org/">https://www.bc-la.org</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="44610362" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/0c3aadf5-3cd7-4391-bae6-aa6eec9f45a4/audio/c80cf576-6048-45a6-9fe0-412fabcb8d42/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Angelita de la Luz, Global Director of Pollination Operations at Beeflow</itunes:title>
      <itunes:author>Kat Merkling, Gabriella Rubert, Daniel Graves, Daniel Arce</itunes:author>
      <itunes:duration>00:46:28</itunes:duration>
      <itunes:summary>When we think about food, we typically don’t think about bugs in a positive light. However, there is an insect who has a crucial role in ensuring successful harvests of healthy crops - bees! Bees are pollinators, meaning they help pollen from one plant get to other in order for plant reproduction to occur. Now, bees don’t behave this way randomly; they’ve evolved to participate in this symbiotic relationship. If we knew all the chemical and biological mechanisms driving this behavior, theoretically, we could leverage those forces to work with the goals of farmers up against unprecedented climate change and population growth.
Companies developing Agriculture-based technology, or Ag-tech, are interested in using science to improve how we grow crops.
Today, I am going to be talking to Angelita de la Luz Global Director of Pollination Operations at Beeflow about how she helps implement ag tech in the field in a pesticide-free, bee-safe way! 
</itunes:summary>
      <itunes:subtitle>When we think about food, we typically don’t think about bugs in a positive light. However, there is an insect who has a crucial role in ensuring successful harvests of healthy crops - bees! Bees are pollinators, meaning they help pollen from one plant get to other in order for plant reproduction to occur. Now, bees don’t behave this way randomly; they’ve evolved to participate in this symbiotic relationship. If we knew all the chemical and biological mechanisms driving this behavior, theoretically, we could leverage those forces to work with the goals of farmers up against unprecedented climate change and population growth.
Companies developing Agriculture-based technology, or Ag-tech, are interested in using science to improve how we grow crops.
Today, I am going to be talking to Angelita de la Luz Global Director of Pollination Operations at Beeflow about how she helps implement ag tech in the field in a pesticide-free, bee-safe way! 
</itunes:subtitle>
      <itunes:keywords>agtech, bees, biotech, agriculture, bioscience</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>19</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">8efe2e7a-1aca-4db2-abca-bdfea6089f65</guid>
      <title>Shawn Singh, CEO of Vistagen - Mental Health Biopharmaceuticals</title>
      <description><![CDATA[<p>Shawn Singh: <a href="https://www.linkedin.com/in/shawnsingh/">https://www.linkedin.com/in/shawnsingh/</a></p><p>Vistagen: <a href="https://www.vistagen.com/">https://www.vistagen.com/</a></p><p>To learn more about BCLA and our events, check out: </p><p><a href="https://www.bc-la.org">https://www.bc-la.org</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Fri, 8 Sep 2023 15:00:00 +0000</pubDate>
      <author>team@bc-la.org (Daniel Arce, Daniel Graves, Leo Ying, Gabriella Rubert, Kathy Grotsch PhD)</author>
      <link>https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals-hRhlp7jv</link>
      <content:encoded><![CDATA[<p>Shawn Singh: <a href="https://www.linkedin.com/in/shawnsingh/">https://www.linkedin.com/in/shawnsingh/</a></p><p>Vistagen: <a href="https://www.vistagen.com/">https://www.vistagen.com/</a></p><p>To learn more about BCLA and our events, check out: </p><p><a href="https://www.bc-la.org">https://www.bc-la.org</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="42943123" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/315a318d-d47f-4089-8620-dc63dee30ac9/audio/2121d2b3-8422-449f-b224-1bb88722d651/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Shawn Singh, CEO of Vistagen - Mental Health Biopharmaceuticals</itunes:title>
      <itunes:author>Daniel Arce, Daniel Graves, Leo Ying, Gabriella Rubert, Kathy Grotsch PhD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/56d99330-0487-4a1e-88d7-a7fba69b001a/3000x3000/insidebiotech-shawnsingh-square.jpg?aid=rss_feed"/>
      <itunes:duration>00:44:43</itunes:duration>
      <itunes:summary>There are high chances that each of you knows someone who has been affected by a mental health disorder. The stigma around these conversations has decreased compared to previous decades, which has opened up a whole new discourse regarding mental health struggles and treatments. Listen to hear Gabriella talk to CEO of Vistagen, Shawn Singh, about current research going on at Vistagen to use nasal sprays to treat mental health disorders in a revolutionary way.</itunes:summary>
      <itunes:subtitle>There are high chances that each of you knows someone who has been affected by a mental health disorder. The stigma around these conversations has decreased compared to previous decades, which has opened up a whole new discourse regarding mental health struggles and treatments. Listen to hear Gabriella talk to CEO of Vistagen, Shawn Singh, about current research going on at Vistagen to use nasal sprays to treat mental health disorders in a revolutionary way.</itunes:subtitle>
      <itunes:keywords>biopharma, biotech, science, bioscience, mentalhealth, startup</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>18</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">6479f051-3ed3-4d03-879b-9892e2f3be70</guid>
      <title>Joyonna Gamble-George, co-founder of SciX, LLC - Intentionality of Diversity, Equity, and Inclusion in Biotech</title>
      <description><![CDATA[<p>More about our guest: Dr. Gamble-George is an award-winning neuroscientist, inventor, entrepreneur, and artist. She graduated from Xavier University in Louisiana with her Bachelor of Science in Biochemistry and Biology/Pre-Med and then went on to earn her Master of Health Administration from the University of South Florida College of Public Health. Ultimately, she completed her PhD in Neuroscience from Vanderbilt University where she studied the role of the endocannabinoid system in stress-induced maladaptations in the brain. </p><p>In addition to her role as a neuroscience researcher, Dr. Gamble-George has founded SciX, LLC, a biotech startup creating a wearable device and mobile application for monitoring risk factors leading to health conditions or behaviors with the goal of predicting, preventing, and managing life-altering events.</p><p>Dr. Gamble-George: <a href="https://www.joyonnagamble.com/">https://www.joyonnagamble.com/</a></p><p>SciX, LLC : <a href="https://scix.io/">https://scix.io/</a></p><p>To learn more about BCLA and our events, check out: https://www.bc-la.org</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 10 Jul 2023 19:00:00 +0000</pubDate>
      <author>team@bc-la.org (Gabriella Rubert, Leo Ying, Joyonna Gamble-George, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/joyonna-gamble-george-co-founder-of-scix-llc-intentionality-of-diversity-equity-and-inclusion-in-biotech-LPhrlquX</link>
      <content:encoded><![CDATA[<p>More about our guest: Dr. Gamble-George is an award-winning neuroscientist, inventor, entrepreneur, and artist. She graduated from Xavier University in Louisiana with her Bachelor of Science in Biochemistry and Biology/Pre-Med and then went on to earn her Master of Health Administration from the University of South Florida College of Public Health. Ultimately, she completed her PhD in Neuroscience from Vanderbilt University where she studied the role of the endocannabinoid system in stress-induced maladaptations in the brain. </p><p>In addition to her role as a neuroscience researcher, Dr. Gamble-George has founded SciX, LLC, a biotech startup creating a wearable device and mobile application for monitoring risk factors leading to health conditions or behaviors with the goal of predicting, preventing, and managing life-altering events.</p><p>Dr. Gamble-George: <a href="https://www.joyonnagamble.com/">https://www.joyonnagamble.com/</a></p><p>SciX, LLC : <a href="https://scix.io/">https://scix.io/</a></p><p>To learn more about BCLA and our events, check out: https://www.bc-la.org</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="48079841" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/e7e2afb2-7cfd-4083-96ca-4c96eaa21015/audio/96d255f9-6100-48a8-976b-c99bc0a5892d/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Joyonna Gamble-George, co-founder of SciX, LLC - Intentionality of Diversity, Equity, and Inclusion in Biotech</itunes:title>
      <itunes:author>Gabriella Rubert, Leo Ying, Joyonna Gamble-George, Daniel Graves</itunes:author>
      <itunes:duration>00:50:04</itunes:duration>
      <itunes:summary>Inside Biotech is BACK from its hiatus and we were so excited to interview Dr. Joyonna Gamble-George, co-founder of SciX, LLC. Dr. Gamble-George is an award-winning neuroscientist, startup advisor, and dedicated science policy advocate - to name a few of her many influential professional roles. Tune in the interview on the newest episode of Inside Biotech to hear Dr. Gamble-George’s story, as well as her thoughts regarding the biotech’s global social responsibility. Many entrepreneurs and early startups fail to include a key factor while developing new tech or hiring talent - diversity. You don’t want to miss this inspiring conversation about the power of intentionality in successful startups and leaders sprinkled with insightful observations of LA’s growing biotech industry. 
</itunes:summary>
      <itunes:subtitle>Inside Biotech is BACK from its hiatus and we were so excited to interview Dr. Joyonna Gamble-George, co-founder of SciX, LLC. Dr. Gamble-George is an award-winning neuroscientist, startup advisor, and dedicated science policy advocate - to name a few of her many influential professional roles. Tune in the interview on the newest episode of Inside Biotech to hear Dr. Gamble-George’s story, as well as her thoughts regarding the biotech’s global social responsibility. Many entrepreneurs and early startups fail to include a key factor while developing new tech or hiring talent - diversity. You don’t want to miss this inspiring conversation about the power of intentionality in successful startups and leaders sprinkled with insightful observations of LA’s growing biotech industry. 
</itunes:subtitle>
      <itunes:keywords>healthtech, equity, biotech, diversity, inclusion</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>17</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">1bbabdf1-725c-4aa5-b0f9-98dd697506b2</guid>
      <title>Damien Wilpitz &amp; Nick Guay-Ross, Co-founders of Experimental Designs Consulting, LLC</title>
      <description><![CDATA[<p>A bit more about our guests: </p><p>As an accomplished management expert with 25 years experience, Damien is a recognized life science executive coach and excels at transforming unassuming scientists into inspiring and influential leaders. He specializes in guiding scientists to not only create high impact lab environments, but also foster captivating and engaging lab cultures that promote creativity and stimulate communication for progress. Focusing on early-stage life sciences, Damien has guided new and experienced scientific leaders through raising over $250M in seed awards and funding, by eliminating uncertainty and channeling dedication into a clear and compelling vision.</p><p>Nick is an adept problem solver and team lead with experience in developing the foundational aspects of life science ventures. With over a decade and a half of management experience, he brings together communication expertise and a skill for creating effective systems that convert innovative ideas into executable actions. Having developed over 200 cross-functional and multi-disciplinary teams, Nick has consulted to create strategies and best practices for both internal collaborations and external partnerships. Focusing on early-stage life sciences, Nick has assisted both new and experienced leaders to raise more than $250M in funding by establishing the foundational blueprint of their scientific visions.</p><p>To learn more, check out: https://experimental-designs.com</p><p>To learn more about BCLA and our events, check out: https://www.bc-la.org</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 19 Sep 2022 23:04:42 +0000</pubDate>
      <author>team@bc-la.org (Damien Wilpitz, Nick Guay-Ross, Ananta Wadhwa, Shay Michael, Kathy Grotsch, Dr. Yewande Pearse, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/damien-wilpitz-nick-guay-ross-co-founders-of-experimental-designs-consulting-llc-XCX9llr3</link>
      <content:encoded><![CDATA[<p>A bit more about our guests: </p><p>As an accomplished management expert with 25 years experience, Damien is a recognized life science executive coach and excels at transforming unassuming scientists into inspiring and influential leaders. He specializes in guiding scientists to not only create high impact lab environments, but also foster captivating and engaging lab cultures that promote creativity and stimulate communication for progress. Focusing on early-stage life sciences, Damien has guided new and experienced scientific leaders through raising over $250M in seed awards and funding, by eliminating uncertainty and channeling dedication into a clear and compelling vision.</p><p>Nick is an adept problem solver and team lead with experience in developing the foundational aspects of life science ventures. With over a decade and a half of management experience, he brings together communication expertise and a skill for creating effective systems that convert innovative ideas into executable actions. Having developed over 200 cross-functional and multi-disciplinary teams, Nick has consulted to create strategies and best practices for both internal collaborations and external partnerships. Focusing on early-stage life sciences, Nick has assisted both new and experienced leaders to raise more than $250M in funding by establishing the foundational blueprint of their scientific visions.</p><p>To learn more, check out: https://experimental-designs.com</p><p>To learn more about BCLA and our events, check out: https://www.bc-la.org</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="47116802" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/340f258d-7a39-43fd-933c-667013461b39/audio/5bfb75b6-d0a4-47d5-8612-d88ac70c5409/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Damien Wilpitz &amp; Nick Guay-Ross, Co-founders of Experimental Designs Consulting, LLC</itunes:title>
      <itunes:author>Damien Wilpitz, Nick Guay-Ross, Ananta Wadhwa, Shay Michael, Kathy Grotsch, Dr. Yewande Pearse, Daniel Graves</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/854bae73-30a4-45e1-956f-4f2452c6c07f/3000x3000/insidebiotech-damien-nick-02.jpg?aid=rss_feed"/>
      <itunes:duration>00:49:04</itunes:duration>
      <itunes:summary>From each pipette tip to every person in a lab, creating the right atmosphere is crucial for success and for discovering the future. Where does a scientist even begin? Enter the experts at EDC - Experimental Design Consulting, LLC - to make the future into a reality. From creating environments that bolster productivity and creativity to recruiting the right people, co-founders, Damien Wilpitz and Nick Guay-Ross, have you covered. Eager to know what works and share it with you, our amazing listeners, we virtually sat down with them to learn more on this episode. </itunes:summary>
      <itunes:subtitle>From each pipette tip to every person in a lab, creating the right atmosphere is crucial for success and for discovering the future. Where does a scientist even begin? Enter the experts at EDC - Experimental Design Consulting, LLC - to make the future into a reality. From creating environments that bolster productivity and creativity to recruiting the right people, co-founders, Damien Wilpitz and Nick Guay-Ross, have you covered. Eager to know what works and share it with you, our amazing listeners, we virtually sat down with them to learn more on this episode. </itunes:subtitle>
      <itunes:keywords>scientific discovery, experimental design consulting, nick guay-ross, biotech, labs, los angeles, damien wilpitz</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>16</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">09e0ca60-22b6-4b21-b98a-d2d01432270f</guid>
      <title>Selin Tamer, Cofounder of Cubtale</title>
      <description><![CDATA[<p>More about Selin Tamer: Selin an industrial engineer with 10+ years experience in data-driven personalization products and has an MBA from INSEAD. She started Cubtale, a hardware and app company that helps newborn parents manage and track routine care 2 years ago after having experienced first-hand the toll of sleep deprivation and the lack of easy to use care tracking solutions for newborns. She is set out to solve this problem in a new way by dramatically simplifying the process to log data and seamlessly connecting it back to health experts.</p><p>To check out Cubtale, visit this website: <a href="https://www.cubtale.com">https://www.cubtale.com</a></p><p>To learn more about what is happening at BCLA, check out our website: <a href="https://www.bc-la.org">https://www.bc-la.org</a>. </p><p>We are always having exciting events and would love to have you join us! </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Wed, 15 Jun 2022 19:00:17 +0000</pubDate>
      <author>team@bc-la.org (Ananta Wadhwa, Kathy Grotsch PhD, Yewande Pearse PhD, Selin Tamer, Daniel Graves, Shay Michael)</author>
      <link>https://inside-biotech.simplecast.com/episodes/selin-tamer-cofounder-of-cubtale-Kw_IOSid</link>
      <content:encoded><![CDATA[<p>More about Selin Tamer: Selin an industrial engineer with 10+ years experience in data-driven personalization products and has an MBA from INSEAD. She started Cubtale, a hardware and app company that helps newborn parents manage and track routine care 2 years ago after having experienced first-hand the toll of sleep deprivation and the lack of easy to use care tracking solutions for newborns. She is set out to solve this problem in a new way by dramatically simplifying the process to log data and seamlessly connecting it back to health experts.</p><p>To check out Cubtale, visit this website: <a href="https://www.cubtale.com">https://www.cubtale.com</a></p><p>To learn more about what is happening at BCLA, check out our website: <a href="https://www.bc-la.org">https://www.bc-la.org</a>. </p><p>We are always having exciting events and would love to have you join us! </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="52808596" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/1c6a4d8b-99f5-43e8-9f3e-e1dd2680c944/audio/c1cb3f5b-c805-4e8d-b8b4-bcc93b2e5bcd/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Selin Tamer, Cofounder of Cubtale</itunes:title>
      <itunes:author>Ananta Wadhwa, Kathy Grotsch PhD, Yewande Pearse PhD, Selin Tamer, Daniel Graves, Shay Michael</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/175434c3-1ae9-4cfe-b30d-6af88e786d37/3000x3000/insidebiotech-ep15-02.jpg?aid=rss_feed"/>
      <itunes:duration>00:36:39</itunes:duration>
      <itunes:summary>Technological advancements and novel creations have facilitated everything from checking into a flight to ensuring a good night&apos;s sleep. However, even though there is an app for almost everything, new parents have not always been able to take full advantage of technology to facilitate care of their newborn babies. Enter Cubtale, Selin Tamer&apos;s small but mighty creation that helps newborn parents track routine care. Intrigued by her story of how she created the #1 Coolest Parenting Tech in 2022, we sat down with Selin Tamer to learn more on our June episode. </itunes:summary>
      <itunes:subtitle>Technological advancements and novel creations have facilitated everything from checking into a flight to ensuring a good night&apos;s sleep. However, even though there is an app for almost everything, new parents have not always been able to take full advantage of technology to facilitate care of their newborn babies. Enter Cubtale, Selin Tamer&apos;s small but mighty creation that helps newborn parents track routine care. Intrigued by her story of how she created the #1 Coolest Parenting Tech in 2022, we sat down with Selin Tamer to learn more on our June episode. </itunes:subtitle>
      <itunes:keywords>selin tamer, coolest parenting tech, new parents, cubtale, la, biotech connection los angeles, inside biotech, biotech, feeding, baby</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>15</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5fda8e36-9b07-4221-8155-e0c4f3329f40</guid>
      <title>Elliot Roth, Founder of Spira Inc.</title>
      <description><![CDATA[<p>To find out more about Spira Inc, check out the website: <a href="https://www.spirainc.com">https://www.spirainc.com</a></p><p>To learn more about what is happening at BCLA, check out our website: <a href="https://www.bc-la.org">https://www.bc-la.org</a>. </p><p>We are always having exciting events and would love to have you join us! </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 16 May 2022 17:37:15 +0000</pubDate>
      <author>team@bc-la.org (Ananta Wadhwa, Dr. Kathy Grotsch, Dr. Yewande Pearse, Shay Michael, Daniel Graves, Elliot Roth)</author>
      <link>https://inside-biotech.simplecast.com/episodes/elliot-roth-founder-of-spira-inc-f7WHnEvK</link>
      <content:encoded><![CDATA[<p>To find out more about Spira Inc, check out the website: <a href="https://www.spirainc.com">https://www.spirainc.com</a></p><p>To learn more about what is happening at BCLA, check out our website: <a href="https://www.bc-la.org">https://www.bc-la.org</a>. </p><p>We are always having exciting events and would love to have you join us! </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="53923146" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/9a82871e-84a7-42f7-b1a7-50ab82017e28/audio/96907eff-004d-4841-9ea4-12ee401fcac1/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Elliot Roth, Founder of Spira Inc.</itunes:title>
      <itunes:author>Ananta Wadhwa, Dr. Kathy Grotsch, Dr. Yewande Pearse, Shay Michael, Daniel Graves, Elliot Roth</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/d10b6554-a88e-4f85-8b67-71c85faf0987/3000x3000/insidebiotech-episode14-insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:37:26</itunes:duration>
      <itunes:summary>An important aspect of what makes food buyable and sellable, food dyes are the underrated artists of the food industry, making your tomato sauce bright red and your sports drink enticingly blue. These dyes, however, are not only often bad for you but also bad for the environment. Imagining a world where these dyes are not only aesthetic, but also nutritional and sustainable, Elliot Roth uses spirulina, a beautifully blue-green colored superfood, to do just that with his company Spira Inc. Intrigued by his story, we sat down to learn more about this colorful vision from Elliot Roth on this episode of ‘Inside Biotech’ from BCLA. </itunes:summary>
      <itunes:subtitle>An important aspect of what makes food buyable and sellable, food dyes are the underrated artists of the food industry, making your tomato sauce bright red and your sports drink enticingly blue. These dyes, however, are not only often bad for you but also bad for the environment. Imagining a world where these dyes are not only aesthetic, but also nutritional and sustainable, Elliot Roth uses spirulina, a beautifully blue-green colored superfood, to do just that with his company Spira Inc. Intrigued by his story, we sat down to learn more about this colorful vision from Elliot Roth on this episode of ‘Inside Biotech’ from BCLA. </itunes:subtitle>
      <itunes:keywords>algae, nutrition, elliot roth, superfood, biotech connection los angeles, biotech, spirulina, food dye, spira</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>14</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5cd0f985-d279-4254-ba00-bdc400296855</guid>
      <title>Shawn Carbonell, MD, Cofounder and CEO of Brazen Bio Inc.</title>
      <description><![CDATA[<p>Shawn Carbonell, MD, PhD, is Cofounder and CEO of Brazen Bio Inc. and Cofounder and Managing Partner of Brazen Capital. He is a graduate of the University of Virginia Medical Scientist Training Program and completed postdocs at Oxford University and UCSF. After a major discovery in brain cancer, Dr. Carbonell quit neurosurgery residency to cofound his first biotech startup, OncoSynergy, Inc. He raised over $20M in dilutive and non-dilutive funding and led the development of the first-in-class therapeutic he invented, OS2966. Today—at Brazen Bio—his mission is to establish the “Y Combinator of biotech,” to help founders overcome the tremendous obstacles that are unique to this industry — obstacles that he personally faced when starting his first company. He sees great value in encouraging more scientists to become CEOs to launch novel technologies beyond the laboratory to advance human health. To learn more, visit his website, <a href="https://www.brainsurgerydropout.com/" target="_blank">https://www.brainsurgerydropout.com</a>. </p><p>Check out <a href="https://www.bc-la.org" target="_blank">bc-la.org</a> for upcoming events, more information on the organization, and lots of exciting updates. </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Thu, 14 Apr 2022 19:09:23 +0000</pubDate>
      <author>team@bc-la.org (Shay Michael, Dr. Shawn Carbonell, Dr. Yewande Pearse, Daniel Graves, Ananta Wadhwa, Dr. Kathy Grotsch)</author>
      <link>https://inside-biotech.simplecast.com/episodes/shawn-carbonell-md-cofounder-and-ceo-of-brazen-bio-inc-Mzo0bnrt</link>
      <content:encoded><![CDATA[<p>Shawn Carbonell, MD, PhD, is Cofounder and CEO of Brazen Bio Inc. and Cofounder and Managing Partner of Brazen Capital. He is a graduate of the University of Virginia Medical Scientist Training Program and completed postdocs at Oxford University and UCSF. After a major discovery in brain cancer, Dr. Carbonell quit neurosurgery residency to cofound his first biotech startup, OncoSynergy, Inc. He raised over $20M in dilutive and non-dilutive funding and led the development of the first-in-class therapeutic he invented, OS2966. Today—at Brazen Bio—his mission is to establish the “Y Combinator of biotech,” to help founders overcome the tremendous obstacles that are unique to this industry — obstacles that he personally faced when starting his first company. He sees great value in encouraging more scientists to become CEOs to launch novel technologies beyond the laboratory to advance human health. To learn more, visit his website, <a href="https://www.brainsurgerydropout.com/" target="_blank">https://www.brainsurgerydropout.com</a>. </p><p>Check out <a href="https://www.bc-la.org" target="_blank">bc-la.org</a> for upcoming events, more information on the organization, and lots of exciting updates. </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="33337602" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/f95a9406-02dd-43d7-b625-29391cf47a42/audio/7bc03ee5-275b-4104-bdb1-87af514cad43/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Shawn Carbonell, MD, Cofounder and CEO of Brazen Bio Inc.</itunes:title>
      <itunes:author>Shay Michael, Dr. Shawn Carbonell, Dr. Yewande Pearse, Daniel Graves, Ananta Wadhwa, Dr. Kathy Grotsch</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/0684ddd2-71d7-499b-aad9-0fdbf7ba81b3/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:34:44</itunes:duration>
      <itunes:summary>From the newest drug to the newest form of matter, scientific discoveries typically start with a drop of solution, a particle accelerator, or a cell in the lab. Getting these scientific discoveries into the hands of consumers, however, requires a great deal of intermediate steps that the scientist who first make the discovery are typically not involved in. In other words, oftentimes, there is a divide between the creators and the sellers; Shawn Carbonell, MD, PhD envisions a world in which the creator and the seller are one in the same. A self proclaimed “brain surgery dropout”, Carbonell turned to creating his own company, Brazen Bio, to help biotech creators and founders to overcome the challenges of selling a product, empower them to take charge in this industry by selling their products themselves, and how to best tell their story and sell their product using social media and scientific storyteller on platforms like TikTok. Intrigued by his journey and a big fan of Dr. Carbonell&apos;s own TikToks, we sat down with him on the inaugural episode of Inside Biotech in 2022 to learn more. </itunes:summary>
      <itunes:subtitle>From the newest drug to the newest form of matter, scientific discoveries typically start with a drop of solution, a particle accelerator, or a cell in the lab. Getting these scientific discoveries into the hands of consumers, however, requires a great deal of intermediate steps that the scientist who first make the discovery are typically not involved in. In other words, oftentimes, there is a divide between the creators and the sellers; Shawn Carbonell, MD, PhD envisions a world in which the creator and the seller are one in the same. A self proclaimed “brain surgery dropout”, Carbonell turned to creating his own company, Brazen Bio, to help biotech creators and founders to overcome the challenges of selling a product, empower them to take charge in this industry by selling their products themselves, and how to best tell their story and sell their product using social media and scientific storyteller on platforms like TikTok. Intrigued by his journey and a big fan of Dr. Carbonell&apos;s own TikToks, we sat down with him on the inaugural episode of Inside Biotech in 2022 to learn more. </itunes:subtitle>
      <itunes:keywords>shawn carbonell, brain surgery, biotech connection los angeles, biotech, scientific story telling, los angeles, brazenbio, tiktok</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>13</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">37cd6df2-7be5-4055-869b-41a0aa773e3b</guid>
      <title>The A in STEAM: Caroline O&apos;Driscoll, Scientific Illustrator</title>
      <description><![CDATA[<p>Caroline O’Driscoll is a professional artist with advanced education in both the life sciences and visual communication. She collaborates with scientists, physicians, and other specialists to transform complex information into visual images that communicate to broad audiences. Her work has been utilized to support medical research, education, clinical care, public relations, and marketing objectives.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 27 Dec 2021 19:19:59 +0000</pubDate>
      <author>team@bc-la.org (Dr. Yewande Pearse, Ananta Wadhwa, Damon Palermo, Caroline O&apos;Driscoll, Kathy Grotsch)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-a-in-steam-caroline-odriscoll-phd-scientific-illustrator-VZER4_fQ</link>
      <content:encoded><![CDATA[<p>Caroline O’Driscoll is a professional artist with advanced education in both the life sciences and visual communication. She collaborates with scientists, physicians, and other specialists to transform complex information into visual images that communicate to broad audiences. Her work has been utilized to support medical research, education, clinical care, public relations, and marketing objectives.</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="39594057" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/721f20a4-0b98-4aa8-a36a-1407a1dcfab3/audio/01dc82e7-c1c2-4cc0-8090-72c13c177c34/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The A in STEAM: Caroline O&apos;Driscoll, Scientific Illustrator</itunes:title>
      <itunes:author>Dr. Yewande Pearse, Ananta Wadhwa, Damon Palermo, Caroline O&apos;Driscoll, Kathy Grotsch</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/378304fa-d38b-428d-8d9c-00db9b0df7a7/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:41:15</itunes:duration>
      <itunes:summary>Open a textbook, open the news app on your phone, or take a look at a billboard. You will probably see a picture of COVID-19, a highly specific diagram of a neuron, or a schematic of the cell cycle. While it might not be evident, these images have been carefully crafted on paper, on a tablet, or on a computer in order to present these pictures to you in a way that is best for relaying this information, making an exciting and engaging visual, while still maintaining accuracy and integrity. Interested in learning more about the process of forming these images and the people behind these incredible images, we sat down with Caroline O&apos;Driscoll, a scientific illustrator at USC, to learn more on our last episode of the A in STEAM in Biotech. Starting January, 2022, we will be taking a short break until the next episode; We will come back with even more exciting news about the Biotech Landscape in Los Angeles!</itunes:summary>
      <itunes:subtitle>Open a textbook, open the news app on your phone, or take a look at a billboard. You will probably see a picture of COVID-19, a highly specific diagram of a neuron, or a schematic of the cell cycle. While it might not be evident, these images have been carefully crafted on paper, on a tablet, or on a computer in order to present these pictures to you in a way that is best for relaying this information, making an exciting and engaging visual, while still maintaining accuracy and integrity. Interested in learning more about the process of forming these images and the people behind these incredible images, we sat down with Caroline O&apos;Driscoll, a scientific illustrator at USC, to learn more on our last episode of the A in STEAM in Biotech. Starting January, 2022, we will be taking a short break until the next episode; We will come back with even more exciting news about the Biotech Landscape in Los Angeles!</itunes:subtitle>
      <itunes:keywords>caroline o&apos;driscoll, inside biotech, usc, scientific illustrator, steam, los angeles</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>12</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2d5dc1a0-c702-4910-a721-7c03392f3d3c</guid>
      <title>The A in STEAM: Claudia Schnugg, Curator and Producer of Art and Science Collaboration</title>
      <description><![CDATA[<p>Dr. Claudia Schnugg is a researcher and curator with an interdisciplinary background in social sciences, business administration, cultural sciences, and the arts. She is a curator in the fields of art & science collaboration, organizational aesthetics, embodied knowledge, and artistic interventions. Partners and clients include  interdisciplinary collectives like <a href="https://www.cos-collective.com/cos-journal/">COS – Challenging Organizations and Society</a>, international research institutions and universities, galleries, art organizations and NGOs operating in the field of art-science-technology, and partners from the field of industry and business like the Human Insights Lab at Accenture. Previously, she held the position of the Creative Director at the <a href="https://venice.sciencegallery.com/">Science Gallery Venice</a>. She worked with institutions like the <a href="https://international.sciencegallery.com/international">Science Gallery International</a>, providing support in developing research proposals and artscience research opportunities. She was head of the Arts Electronica Residency Network at the <a href="http://www.aec.at/">Ars Electronica</a> Futurelab, where she developed the residency program and curated, mentored, and produced artistic residency projects at numerous scientific institutions. Those included EU projects (<a href="http://www.sparksproject.eu/">Sparks</a>, <a href="http://connectingcities.net/">Connecting Cities Network</a>, <a href="http://www.aec.at/artandscience/en/">European Digital Art and Science Network</a>) and programs in cooperation with world-class institutions like <a href="http://www.cern.ch/">CERN</a>, <a href="http://www.eso.org/">ESO</a> (European Southern Observatories), <a href="http://www.qut.edu.au/">Queensland University of Technology</a>, <a href="http://www.voestalpine.com/">voestalpine</a>, and <a href="http://www.ctia.kr/">CTIA</a> (Chungnam Technology Industry Agency).</p><p>To learn more about our guest, you can check out this website: https://www.claudiaschnugg.com</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Tue, 16 Nov 2021 20:14:40 +0000</pubDate>
      <author>team@bc-la.org (Dr. Yewande Pearse, Kathy Grotsch, Ananta Wadhwa, Damon Palermo, Claudia Schnugg)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-a-in-steam-claudia-schnugg-curator-and-produce-of-art-and-science-collaboration-Bmdosvqk</link>
      <content:encoded><![CDATA[<p>Dr. Claudia Schnugg is a researcher and curator with an interdisciplinary background in social sciences, business administration, cultural sciences, and the arts. She is a curator in the fields of art & science collaboration, organizational aesthetics, embodied knowledge, and artistic interventions. Partners and clients include  interdisciplinary collectives like <a href="https://www.cos-collective.com/cos-journal/">COS – Challenging Organizations and Society</a>, international research institutions and universities, galleries, art organizations and NGOs operating in the field of art-science-technology, and partners from the field of industry and business like the Human Insights Lab at Accenture. Previously, she held the position of the Creative Director at the <a href="https://venice.sciencegallery.com/">Science Gallery Venice</a>. She worked with institutions like the <a href="https://international.sciencegallery.com/international">Science Gallery International</a>, providing support in developing research proposals and artscience research opportunities. She was head of the Arts Electronica Residency Network at the <a href="http://www.aec.at/">Ars Electronica</a> Futurelab, where she developed the residency program and curated, mentored, and produced artistic residency projects at numerous scientific institutions. Those included EU projects (<a href="http://www.sparksproject.eu/">Sparks</a>, <a href="http://connectingcities.net/">Connecting Cities Network</a>, <a href="http://www.aec.at/artandscience/en/">European Digital Art and Science Network</a>) and programs in cooperation with world-class institutions like <a href="http://www.cern.ch/">CERN</a>, <a href="http://www.eso.org/">ESO</a> (European Southern Observatories), <a href="http://www.qut.edu.au/">Queensland University of Technology</a>, <a href="http://www.voestalpine.com/">voestalpine</a>, and <a href="http://www.ctia.kr/">CTIA</a> (Chungnam Technology Industry Agency).</p><p>To learn more about our guest, you can check out this website: https://www.claudiaschnugg.com</p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="28672879" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/76e49b4d-1cbc-4dbf-bd3a-d31632fd6a8a/audio/e88eca9f-b080-430e-9f73-eeb1efb2f8d7/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The A in STEAM: Claudia Schnugg, Curator and Producer of Art and Science Collaboration</itunes:title>
      <itunes:author>Dr. Yewande Pearse, Kathy Grotsch, Ananta Wadhwa, Damon Palermo, Claudia Schnugg</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/720ac566-3b43-47af-8bad-85e2f335cbc7/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:52</itunes:duration>
      <itunes:summary>Solving a problem requires a variety of puzzle pieces that are carefully crafted to fit together into a solution. Using art to solve technical, organizational, and more logical problems is often an overlooked solution to solving the problems of tomorrow. While people often have functional fixedness when it comes to problem solving, often it is useful to flip narratives, use input from interdisciplinary fields, and generally draw on ideas from all fields - be they artistic or scientific -  to come to the best solution and fit together all the puzzle pieces. Dr. Claudia Schnugg, a researcher and curator with an interdisciplinary background in social sciences, business administration, cultural sciences, and the artist, is adept at juxtaposing art and science to create novel ideas, solutions, and questions for the future. We sat down with her on our 3rd episode of our series, “The A in STEAM: Art and Design in Biotech” to learn more about how she crafts these puzzles.</itunes:summary>
      <itunes:subtitle>Solving a problem requires a variety of puzzle pieces that are carefully crafted to fit together into a solution. Using art to solve technical, organizational, and more logical problems is often an overlooked solution to solving the problems of tomorrow. While people often have functional fixedness when it comes to problem solving, often it is useful to flip narratives, use input from interdisciplinary fields, and generally draw on ideas from all fields - be they artistic or scientific -  to come to the best solution and fit together all the puzzle pieces. Dr. Claudia Schnugg, a researcher and curator with an interdisciplinary background in social sciences, business administration, cultural sciences, and the artist, is adept at juxtaposing art and science to create novel ideas, solutions, and questions for the future. We sat down with her on our 3rd episode of our series, “The A in STEAM: Art and Design in Biotech” to learn more about how she crafts these puzzles.</itunes:subtitle>
      <itunes:keywords>science collaboration, organizational aesthetics, interdisciplinary, art-science-technology, inside biotech, biotech, bcla, technology, science, steam, cultural sciences, art</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>11</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5a160fc5-e85b-4039-9a4f-494a99075d18</guid>
      <title>The A in STEAM: Rita Blaik, Education Director of the CNSI at UCLA</title>
      <description><![CDATA[<p>Rita Blaik is a multidisciplinary scientist and artist based in Los Angeles, California. Her life's goal is to find new and innovative ways of communicating science to people through interactive discussions, art, and other media. Since 2009 she has been an instructor for the Sci|Art Nanolab and from 2011-2012, was the Art|Sci Center Networking Outreach Coordinator. She had her first solo exhibition at the Art|Sci Center, Altered States, in Fall 2012. Rita received her PhD in Materials Science & Engineering at UCLA. She is a proud fellow of the NSF IGERT Clean Energy for Green Industry fellowship and works with Professor Bruce Dunn on biological fuel cell systems and architectures. You can learn more about her incredible work here: <a href="https://ritablaik.com/">https://ritablaik.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Tue, 19 Oct 2021 18:52:54 +0000</pubDate>
      <author>team@bc-la.org (Kathy Grotsch, Ananta Wadhwa, Damon Palermo, Dr. Rita Blaik, Dr. Yewande Pearse)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-a-in-steam-rita-blaik-education-director-of-the-cnsi-at-ucla-0W_6Xx19</link>
      <content:encoded><![CDATA[<p>Rita Blaik is a multidisciplinary scientist and artist based in Los Angeles, California. Her life's goal is to find new and innovative ways of communicating science to people through interactive discussions, art, and other media. Since 2009 she has been an instructor for the Sci|Art Nanolab and from 2011-2012, was the Art|Sci Center Networking Outreach Coordinator. She had her first solo exhibition at the Art|Sci Center, Altered States, in Fall 2012. Rita received her PhD in Materials Science & Engineering at UCLA. She is a proud fellow of the NSF IGERT Clean Energy for Green Industry fellowship and works with Professor Bruce Dunn on biological fuel cell systems and architectures. You can learn more about her incredible work here: <a href="https://ritablaik.com/">https://ritablaik.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="36690173" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/577395ec-9160-4a6d-a6aa-19caafdad5c9/audio/d7ec137b-9132-4a43-afc6-fb0d275d3f3d/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The A in STEAM: Rita Blaik, Education Director of the CNSI at UCLA</itunes:title>
      <itunes:author>Kathy Grotsch, Ananta Wadhwa, Damon Palermo, Dr. Rita Blaik, Dr. Yewande Pearse</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/e894437c-db68-42c8-8771-c4bfc0364e47/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:38:14</itunes:duration>
      <itunes:summary>Leonardo DaVinci once said, “To develop a complete mind: Study the science of art; Study the art of science” - to him, the two were intricately intertwined and informed and enhanced the other. Two disciplines that are normally treated as the antithesis of each other, we at ‘Inside Biotech’ were ready to take a deep dive into this matter - we had the great pleasure to sit down with Rita Blaik, Director of Education at CNSI at UCLA, to learn about how she is taking  taking Da Vinci’s words to heart. Come along with us on a colorful journey on the second episode of BCLA’s Inside Biotech, Series 3: the A in STEAM, Art and Design in Biotech. </itunes:summary>
      <itunes:subtitle>Leonardo DaVinci once said, “To develop a complete mind: Study the science of art; Study the art of science” - to him, the two were intricately intertwined and informed and enhanced the other. Two disciplines that are normally treated as the antithesis of each other, we at ‘Inside Biotech’ were ready to take a deep dive into this matter - we had the great pleasure to sit down with Rita Blaik, Director of Education at CNSI at UCLA, to learn about how she is taking  taking Da Vinci’s words to heart. Come along with us on a colorful journey on the second episode of BCLA’s Inside Biotech, Series 3: the A in STEAM, Art and Design in Biotech. </itunes:subtitle>
      <itunes:keywords>architectures, cnsi, sci|art nanolab, inside biotech, rita blaik, ucla, los angeles, biological fuel, art in biotech</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>10</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">0b5b79be-0da7-4493-ad6a-a07552f60cb4</guid>
      <title>The A in STEAM: Alicia Pandimos Maurer, Cannon Design</title>
      <description><![CDATA[<p>A little bit more about our guest: Alicia Pandimos Maurer, AIA, LEED AP, is a laboratory designer whose 20+ years’ experience has spanned an array of specialty sciences such as genetics, gene and cell therapy, personalized medicine, microbiology, cell culture, and PCR and sequencing. From planning through construction administration and post-occupancy, Alicia has led both consultants and internal teams through all project phases. She considers herself a conduit for information to flow back and forth between the design and construction team and the owner and end-users. Passionate about sustainable lab design, Alicia is a thought-leader in this field, helping found the Colorado chapter of the International Institute for Sustainable Laboratories (I2SL) and currently sits on the San Diego board for I2SL. You can learn more at: <a href="https://www.cannondesign.com/">https://www.cannondesign.com </a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Thu, 16 Sep 2021 04:53:17 +0000</pubDate>
      <author>team@bc-la.org (Damon Palermo, Kathy Grostch, Daniel Graves, Alicia Pandimos Maurer, Ananta Wadhwa, Dr. Yewande Pearse)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-a-in-steam-alicia-pandimos-maurer-cannon-design-UN5ysMGd</link>
      <content:encoded><![CDATA[<p>A little bit more about our guest: Alicia Pandimos Maurer, AIA, LEED AP, is a laboratory designer whose 20+ years’ experience has spanned an array of specialty sciences such as genetics, gene and cell therapy, personalized medicine, microbiology, cell culture, and PCR and sequencing. From planning through construction administration and post-occupancy, Alicia has led both consultants and internal teams through all project phases. She considers herself a conduit for information to flow back and forth between the design and construction team and the owner and end-users. Passionate about sustainable lab design, Alicia is a thought-leader in this field, helping found the Colorado chapter of the International Institute for Sustainable Laboratories (I2SL) and currently sits on the San Diego board for I2SL. You can learn more at: <a href="https://www.cannondesign.com/">https://www.cannondesign.com </a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="41227955" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/96b802e8-6878-4016-9714-908294376fc7/audio/d72dfe40-cdde-43ae-a7fa-c9ecf03e741d/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The A in STEAM: Alicia Pandimos Maurer, Cannon Design</itunes:title>
      <itunes:author>Damon Palermo, Kathy Grostch, Daniel Graves, Alicia Pandimos Maurer, Ananta Wadhwa, Dr. Yewande Pearse</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/7edc9699-fbb2-4556-ba35-102f97217ba7/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:42:57</itunes:duration>
      <itunes:summary>Named #2 Most Innovative Company in North America, Cannon Design is a pioneer in transforming places, spaces, and creating buildings that are the epitome of innovative. From the Kaiser Permanente Bernard J. Tyson School of Medicine to the Novartis Institutes for Biomedical Research, Cambridge Campus, Cannon Design has created some of the most accessible and successful environments to allow medicine, scientific research, and biotech to flourish. To learn how much the “space makes or breaks a place”, especially in laboratories, science, and biotechnology, we virtually sat down with Alicia Pandimos Maurer, AIA, LEED AP, a laboratory designer who helps create these architectural masterpieces. </itunes:summary>
      <itunes:subtitle>Named #2 Most Innovative Company in North America, Cannon Design is a pioneer in transforming places, spaces, and creating buildings that are the epitome of innovative. From the Kaiser Permanente Bernard J. Tyson School of Medicine to the Novartis Institutes for Biomedical Research, Cambridge Campus, Cannon Design has created some of the most accessible and successful environments to allow medicine, scientific research, and biotech to flourish. To learn how much the “space makes or breaks a place”, especially in laboratories, science, and biotechnology, we virtually sat down with Alicia Pandimos Maurer, AIA, LEED AP, a laboratory designer who helps create these architectural masterpieces. </itunes:subtitle>
      <itunes:keywords>design, insidebiotech, architecture, cannon design, innovation, biotech, steam, los angeles, art</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>9</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">9529f1ba-5e94-416d-8505-76e23813ec90</guid>
      <title>The Dish on Biotech in Food: Robert Goldberg, Professor at UCLA</title>
      <description><![CDATA[<p>More About Professor Goldberg: Bob Goldberg is a plant molecular biologist who specializes in the area of plant genomics. The goal of his research has been to understand how plant cells differentiate and how genes are activated selectively in specialized cell types during plant development. Professor Goldberg's research has provided a conceptual foundation for the processes that regulate gene expression in higher plants. In collaboration with others, he utilized genes identified in his laboratory to develop a novel system to genetically engineer for male fertility control in crop plants. This system was used to develop new hybrid varieties of canola plants that have significantly increased yields of oil. His current research is using state-of-the-art genomics technologies to identify all of the genes required to make a seed. Professor Goldberg received a B.S. in Botany at Ohio University, and M.S. and Ph.D. degrees in Plant Genetics from The University of Arizona. Professor Goldberg was a Postdoctoral Fellow at the California Institute of Technology and joined the UCLA faculty in 1976. Professor Goldberg served twice as Director of the Plant Genetics Program at the USDA, has been on the Editorial Boards of many internationally recognized journals such as Science, and was the Founding Editor and Editor-In-Chief of The Plant Cell, the leading journal in the area of plant molecular biology. He has been the organizer of many major international plant molecular biology meetings, is the Director of The Seed Institute - an intercampus institute without walls within the University of California dedicated to unraveling the processes that control seed development. Professor Goldberg has given hundreds of lectures on his research world-wide, and has received several awards recognizing his contributions to the field of plant molecular biology. These include election to the National Academy of Sciences, the National Order for Scientific Merit from the President of Brazil, being named as a UCLA Faculty Research Lecturer, and being listed as making one of the "top 15" Discoveries in UCLA's 75-year history. Professor Goldberg is highly committed to undergraduate and graduate education and is an "expert" in making science "come alive." Professor Goldberg has received Distinguished Teaching Awards from the Department of Biology and the Department of Molecular, Cell, and Developmental Biology, and was awarded the Luckmann Distinguished Teaching Award from the Academic Senate. He has also been awarded the Gold Shield Prize for Excellence in Research and Undergraduate Education by the Academic Senate and was named as one of the "top 20" Professors in UCLA's 75-year history. Recently, Professor Goldberg was awarded a Howard Hughes Medical Institute University Professorship with the goal of expanding undergraduate opportunities in discovery-oriented research. </p><p>To learn more, you can visit: https://research.mcdb.ucla.edu/Goldberg/index.htm </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Thu, 26 Aug 2021 21:39:57 +0000</pubDate>
      <author>team@bc-la.org (Daniel Graves, Dr. Yewande Pearse, Ananta Wadhwa, Damon Palermo, Kathy Grotsch, Dr. Robert Goldberg)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-dish-on-biotech-in-food-robert-goldberg-professor-at-ucla-hKeFxXY2</link>
      <content:encoded><![CDATA[<p>More About Professor Goldberg: Bob Goldberg is a plant molecular biologist who specializes in the area of plant genomics. The goal of his research has been to understand how plant cells differentiate and how genes are activated selectively in specialized cell types during plant development. Professor Goldberg's research has provided a conceptual foundation for the processes that regulate gene expression in higher plants. In collaboration with others, he utilized genes identified in his laboratory to develop a novel system to genetically engineer for male fertility control in crop plants. This system was used to develop new hybrid varieties of canola plants that have significantly increased yields of oil. His current research is using state-of-the-art genomics technologies to identify all of the genes required to make a seed. Professor Goldberg received a B.S. in Botany at Ohio University, and M.S. and Ph.D. degrees in Plant Genetics from The University of Arizona. Professor Goldberg was a Postdoctoral Fellow at the California Institute of Technology and joined the UCLA faculty in 1976. Professor Goldberg served twice as Director of the Plant Genetics Program at the USDA, has been on the Editorial Boards of many internationally recognized journals such as Science, and was the Founding Editor and Editor-In-Chief of The Plant Cell, the leading journal in the area of plant molecular biology. He has been the organizer of many major international plant molecular biology meetings, is the Director of The Seed Institute - an intercampus institute without walls within the University of California dedicated to unraveling the processes that control seed development. Professor Goldberg has given hundreds of lectures on his research world-wide, and has received several awards recognizing his contributions to the field of plant molecular biology. These include election to the National Academy of Sciences, the National Order for Scientific Merit from the President of Brazil, being named as a UCLA Faculty Research Lecturer, and being listed as making one of the "top 15" Discoveries in UCLA's 75-year history. Professor Goldberg is highly committed to undergraduate and graduate education and is an "expert" in making science "come alive." Professor Goldberg has received Distinguished Teaching Awards from the Department of Biology and the Department of Molecular, Cell, and Developmental Biology, and was awarded the Luckmann Distinguished Teaching Award from the Academic Senate. He has also been awarded the Gold Shield Prize for Excellence in Research and Undergraduate Education by the Academic Senate and was named as one of the "top 20" Professors in UCLA's 75-year history. Recently, Professor Goldberg was awarded a Howard Hughes Medical Institute University Professorship with the goal of expanding undergraduate opportunities in discovery-oriented research. </p><p>To learn more, you can visit: https://research.mcdb.ucla.edu/Goldberg/index.htm </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="40620987" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/e8eec2ba-4521-4909-895f-0c36f2eed911/audio/0fc71a37-6d76-410e-82a6-d1327455480f/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The Dish on Biotech in Food: Robert Goldberg, Professor at UCLA</itunes:title>
      <itunes:author>Daniel Graves, Dr. Yewande Pearse, Ananta Wadhwa, Damon Palermo, Kathy Grotsch, Dr. Robert Goldberg</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/a0c15bef-c6af-4097-b21d-819867df164e/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:42:19</itunes:duration>
      <itunes:summary>According to a study done by Michigan State University, the per capita farmable land worldwide was 0.42 hectares in 1960. It will be 0.19 hectares in 2050. We, however, are dependent on seed crops and farming. We need a superhero seed that can grow faster, bigger, better, and all with less space. To get to this seed, we need to learn about the building blocks - the DNA - that enable the building of a seed and in turn, a plant. Join us in hearing about the future of food from Dr. Robert Goldberg, a professor at UCLA, in our final episode of our second series of ‘The Dish on Biotech In Food&apos;&apos; on BCLA’s podcast, Inside Biotech. </itunes:summary>
      <itunes:subtitle>According to a study done by Michigan State University, the per capita farmable land worldwide was 0.42 hectares in 1960. It will be 0.19 hectares in 2050. We, however, are dependent on seed crops and farming. We need a superhero seed that can grow faster, bigger, better, and all with less space. To get to this seed, we need to learn about the building blocks - the DNA - that enable the building of a seed and in turn, a plant. Join us in hearing about the future of food from Dr. Robert Goldberg, a professor at UCLA, in our final episode of our second series of ‘The Dish on Biotech In Food&apos;&apos; on BCLA’s podcast, Inside Biotech. </itunes:subtitle>
      <itunes:keywords>dna sequencing, genetic modification, seeds, biotech connection los angeles, molecular biology, biotech, crops, future of food, robert goldberg, genomics, ucla, food crisis, plants</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>8</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">49115445-8ec4-45fa-9832-17bfc8dbb5b2</guid>
      <title>The Dish on Biotech in Food: Ross Mackay, Found &amp; CEO of daring foods</title>
      <description><![CDATA[<p>With flavors spanning from Lemon and Herb to Cajun, Daring’s meatless chicken is almost synonymous in flavor, taste, and texture with its real counterpart. Not only are they focused on perfecting the product itself, they are also working on being sustainable and supporting like-minded organizations, a goal that has even been supported by Drake! On our third episode of ‘The Dish on Biotech in Food’, we virtually sat down with Ross Mackay, the CEO and Founder, to learn more about his vision. A little bit more about Mackay: Ross Mackay is the founder and CEO of Daring, the leader in clean plant-based chicken. In 2018, Mackay set out to create a plant-based chicken that mimics the real thing – both in texture and taste. He knew if he could crack the code on a better-for-you plant-based chicken, he would positively impact both the planet and consumer wellness. He launched with Original Daring Pieces in the U.S in 2019, propelling the plant-based category by locking in nationwide retail partners, investors, DTC platform, giveback program, and future innovations – all in his first calendar year. In December 2020, he earned the Forbes 30-Under-30 designation within the Food & Drink category. Mackay, currently under-30 and a vegan athlete, grew up playing international tennis under mentorship from Judy Murray. His competitive background and devotion to a healthy active lifestyle propelled Mackay to start his entrepreneurial career at the age of 22. He uses his passion and experience in early-stage business formation and sales marketing to position Daring for significant growth.</p><p>You can learn more here: <a href="https://daring.com/">https://daring.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Fri, 16 Jul 2021 16:25:30 +0000</pubDate>
      <author>team@bc-la.org (Kathy Grotsch, Dr. Yewande Pearse, Damon Palermo, Ross Mackay, Ananta Wadhwa)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-dish-on-biotech-in-food-ross-mackay-found-ceo-of-daring-foods-298GKVRU</link>
      <content:encoded><![CDATA[<p>With flavors spanning from Lemon and Herb to Cajun, Daring’s meatless chicken is almost synonymous in flavor, taste, and texture with its real counterpart. Not only are they focused on perfecting the product itself, they are also working on being sustainable and supporting like-minded organizations, a goal that has even been supported by Drake! On our third episode of ‘The Dish on Biotech in Food’, we virtually sat down with Ross Mackay, the CEO and Founder, to learn more about his vision. A little bit more about Mackay: Ross Mackay is the founder and CEO of Daring, the leader in clean plant-based chicken. In 2018, Mackay set out to create a plant-based chicken that mimics the real thing – both in texture and taste. He knew if he could crack the code on a better-for-you plant-based chicken, he would positively impact both the planet and consumer wellness. He launched with Original Daring Pieces in the U.S in 2019, propelling the plant-based category by locking in nationwide retail partners, investors, DTC platform, giveback program, and future innovations – all in his first calendar year. In December 2020, he earned the Forbes 30-Under-30 designation within the Food & Drink category. Mackay, currently under-30 and a vegan athlete, grew up playing international tennis under mentorship from Judy Murray. His competitive background and devotion to a healthy active lifestyle propelled Mackay to start his entrepreneurial career at the age of 22. He uses his passion and experience in early-stage business formation and sales marketing to position Daring for significant growth.</p><p>You can learn more here: <a href="https://daring.com/">https://daring.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="32359697" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/a6bc4261-070a-4f20-95a0-390064637f7e/audio/a3db5e16-d5e4-4c60-982b-e321fb8ff314/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The Dish on Biotech in Food: Ross Mackay, Found &amp; CEO of daring foods</itunes:title>
      <itunes:author>Kathy Grotsch, Dr. Yewande Pearse, Damon Palermo, Ross Mackay, Ananta Wadhwa</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/24071eaa-1994-4263-9381-5eb63415e68d/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:33:42</itunes:duration>
      <itunes:summary>The frozen isle in the grocery store is transforming; While there used to be a variety of chicken nuggets and french fries, there is now an even larger assortment of plant-based meat products including a “chicken” from a company with daring mission - changing the chicken industry one package of frozen meatless chicken at a time. We spoke with the Founder and CEO of Daring, Ross Mackay, to learn more about how the company aims to take on “big chicken” in our 3rd episode of this series, the Dish on Food in Biotech, of the BCLA podcast, &apos;Inside Biotech&apos; this month. 
</itunes:summary>
      <itunes:subtitle>The frozen isle in the grocery store is transforming; While there used to be a variety of chicken nuggets and french fries, there is now an even larger assortment of plant-based meat products including a “chicken” from a company with daring mission - changing the chicken industry one package of frozen meatless chicken at a time. We spoke with the Founder and CEO of Daring, Ross Mackay, to learn more about how the company aims to take on “big chicken” in our 3rd episode of this series, the Dish on Food in Biotech, of the BCLA podcast, &apos;Inside Biotech&apos; this month. 
</itunes:subtitle>
      <itunes:keywords>daringfoods, drake, food, health, inside, biotech, bcla, chicken industry, chicken, plantbased</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>7</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">96a4f07f-e4e3-461b-8a6a-0749e45dd986</guid>
      <title>The Dish on Biotech in Food: Julianne Hummelberg, Vice President of Investment at PowerPlant Partners</title>
      <description><![CDATA[<p>By 2050, we will need to increase food production by about 60% to accommodate an ever growing population. The way we make and consume food now, however, is not conducive or a sustainable way to meet these needs. Enter PowerPlant Partners, a firm that is investing in companies and products that will enable us to meet this goal and more! As the Vice President of the Investment Team of PowerPlant Partners, Julianne Hummelberg gives us the inside scoop on the company and these products. A little bit about Julianne: Julianne leads deal sourcing and execution, and helps PowerPlant portfolio companies create and capture value as a board member of portfolio company Veggie Grill and board observer to Zero Egg, Rae Wellness, REBBL, The Coconut Collaborative, OWYN and Jot Coffee. She earned her MBA from Columbia Business School where she was a Venture and Private Equity Fellow and President of the Healthy Living Club. She also holds a BA in Economics from Wake Forest University, where she graduated cum laude, and an associate degree in Economics from the London School of Economics and Political Science. In her free time, she enjoys being with her rescue dogs August Remington, traveling internationally, HIIT workouts, learning Spanish and contributing as a board member of Synergist Network, a non-profit organization that works towards gender parity in the private equity and venture capital industries. If you are interested in learning more, please visit the website: <a href="https://powerplantpartners.co/">https://powerplantpartners.co</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Thu, 17 Jun 2021 03:11:04 +0000</pubDate>
      <author>team@bc-la.org (Ananta Wadhwa, Kathy Grotsch, Julianne Hummelberg, Dr. Yewande Pearse, Daniel Graves, Damon Palermo)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-dish-on-biotech-in-food-julianne-hummelberg-vice-president-of-investment-at-powerplant-partners-dHJsy3uS</link>
      <content:encoded><![CDATA[<p>By 2050, we will need to increase food production by about 60% to accommodate an ever growing population. The way we make and consume food now, however, is not conducive or a sustainable way to meet these needs. Enter PowerPlant Partners, a firm that is investing in companies and products that will enable us to meet this goal and more! As the Vice President of the Investment Team of PowerPlant Partners, Julianne Hummelberg gives us the inside scoop on the company and these products. A little bit about Julianne: Julianne leads deal sourcing and execution, and helps PowerPlant portfolio companies create and capture value as a board member of portfolio company Veggie Grill and board observer to Zero Egg, Rae Wellness, REBBL, The Coconut Collaborative, OWYN and Jot Coffee. She earned her MBA from Columbia Business School where she was a Venture and Private Equity Fellow and President of the Healthy Living Club. She also holds a BA in Economics from Wake Forest University, where she graduated cum laude, and an associate degree in Economics from the London School of Economics and Political Science. In her free time, she enjoys being with her rescue dogs August Remington, traveling internationally, HIIT workouts, learning Spanish and contributing as a board member of Synergist Network, a non-profit organization that works towards gender parity in the private equity and venture capital industries. If you are interested in learning more, please visit the website: <a href="https://powerplantpartners.co/">https://powerplantpartners.co</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="45361154" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/6252471d-825c-411f-8e13-599a40529b9e/audio/147dcee5-87ac-4962-8e79-936b9d00f683/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The Dish on Biotech in Food: Julianne Hummelberg, Vice President of Investment at PowerPlant Partners</itunes:title>
      <itunes:author>Ananta Wadhwa, Kathy Grotsch, Julianne Hummelberg, Dr. Yewande Pearse, Daniel Graves, Damon Palermo</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/32def543-8c2c-42bc-9a2e-d6f4473f0eb0/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:47:15</itunes:duration>
      <itunes:summary>Have you ever walked around the supermarket and noticed a new product such as a plant-based egg, a new plant-based milk, or a bean-based chip? Chances are you have come across a company or product in PowerPlant Partner’s extensive portfolio! A Los Angeles based growth equity firm, PowerPlant Partners is on the hunt for the next consumer wellness companies or products. With the goal of creating a sustainable future in mind, PowerPlant Partners invests in plant-based products, new ways to keep produce clean, and so much more. Excited about the prospect of a delicious and sustainable future, we sat down with the Vice President of the Investment Team, Julianne Hummelberg, to learn more. Join us on a delicious journey from concept to shelf in the 2nd episode of our second series, ‘The Dish on Biotech in Food’ today! </itunes:summary>
      <itunes:subtitle>Have you ever walked around the supermarket and noticed a new product such as a plant-based egg, a new plant-based milk, or a bean-based chip? Chances are you have come across a company or product in PowerPlant Partner’s extensive portfolio! A Los Angeles based growth equity firm, PowerPlant Partners is on the hunt for the next consumer wellness companies or products. With the goal of creating a sustainable future in mind, PowerPlant Partners invests in plant-based products, new ways to keep produce clean, and so much more. Excited about the prospect of a delicious and sustainable future, we sat down with the Vice President of the Investment Team, Julianne Hummelberg, to learn more. Join us on a delicious journey from concept to shelf in the 2nd episode of our second series, ‘The Dish on Biotech in Food’ today! </itunes:subtitle>
      <itunes:keywords>plant-based, food, health, inside biotech, biotech, sustainability, science, los angeles, connection, wellness, dish, powerplant partners</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>6</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2c2f8f29-5204-4bef-b9ed-fdc8d7088f4a</guid>
      <title>The Dish on Biotech in Food: Ryan Bethencourt, Founder and CEO of Wild Earth</title>
      <description><![CDATA[<p> Despite the popular trope that our furry friends only want to eat meat and chew on bones, dogs are actually omnivores meaning that their diet does not have to consist of only or mainly meat products. While doting owners want to feed their dogs the best food to keep their loving companions in tip-top shape, there are many times that a plant based dog food might be best for them. Plant based dog food? Where does one buy that? One California Startup, Wild Earth, is delivering it right to your door! Pitched on SharkTank, Wild Earth has developed a high protein, plant based dog food using Koji that will have any dog happily munching away. Not only is the food great for dogs, it is also a meat free alternative that relieves pressure on the environment too as dog food is a huge source of meat need and usage. You can learn more at: <a href="https://wildearth.com/">https://wildearth.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Sat, 15 May 2021 17:31:57 +0000</pubDate>
      <author>team@bc-la.org (Damon Palermo, Kathy Grotsch, Daniel Graves, Ryan Bethencourt, Ananta Wadhwa, Dr. Yewande Pearse)</author>
      <link>https://inside-biotech.simplecast.com/episodes/the-dish-on-biotech-in-food-ryan-bethencourt-founder-and-ceo-of-wild-earth-9PkPgQ1q</link>
      <content:encoded><![CDATA[<p> Despite the popular trope that our furry friends only want to eat meat and chew on bones, dogs are actually omnivores meaning that their diet does not have to consist of only or mainly meat products. While doting owners want to feed their dogs the best food to keep their loving companions in tip-top shape, there are many times that a plant based dog food might be best for them. Plant based dog food? Where does one buy that? One California Startup, Wild Earth, is delivering it right to your door! Pitched on SharkTank, Wild Earth has developed a high protein, plant based dog food using Koji that will have any dog happily munching away. Not only is the food great for dogs, it is also a meat free alternative that relieves pressure on the environment too as dog food is a huge source of meat need and usage. You can learn more at: <a href="https://wildearth.com/">https://wildearth.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="45313088" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/0c5d762b-e8d8-4649-aeac-175737e6e995/audio/f9de4aa7-cd81-488a-a7a2-675b5992e7f0/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>The Dish on Biotech in Food: Ryan Bethencourt, Founder and CEO of Wild Earth</itunes:title>
      <itunes:author>Damon Palermo, Kathy Grotsch, Daniel Graves, Ryan Bethencourt, Ananta Wadhwa, Dr. Yewande Pearse</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/05abb0cd-de6a-4c57-a058-44aa56425a03/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:47:12</itunes:duration>
      <itunes:summary>As we aim to fill ourselves with the highest quality, most nutritious, and best food, we love to do the same for our unwavering companies: our pups! “You are what you eat” is as relevant to them as it is for us. Again, like us, dogs are omnivores that definitely benefit from a diet varied in sources of nutrients including plant-based protein and other non-meat foods. Dog food, however, often does not cater to this nuance. Wild Earth, a CA Startup, is trying to change that one delivery at a time. To learn more, we virtually sat down with the CEO of Wild Earth, Ryan Bethencourt, on our first episode of our second series: The Dish on Biotech in Food.</itunes:summary>
      <itunes:subtitle>As we aim to fill ourselves with the highest quality, most nutritious, and best food, we love to do the same for our unwavering companies: our pups! “You are what you eat” is as relevant to them as it is for us. Again, like us, dogs are omnivores that definitely benefit from a diet varied in sources of nutrients including plant-based protein and other non-meat foods. Dog food, however, often does not cater to this nuance. Wild Earth, a CA Startup, is trying to change that one delivery at a time. To learn more, we virtually sat down with the CEO of Wild Earth, Ryan Bethencourt, on our first episode of our second series: The Dish on Biotech in Food.</itunes:subtitle>
      <itunes:keywords>koji, dog, food, earth, biotech, wild, ryan, bethencourt, los angeles, connection, plant based, dish</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>5</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">0f5ccd64-f316-4123-a818-1083ffc3ae57</guid>
      <title>Alternative Careers in Biotech: Peter Mponzi, Former R&amp;D Senior Process Designer at Lyxia</title>
      <description><![CDATA[<p>In Biotech, people are often on the hunt for more sustainable ways for humans to be energized in two major ways: through food and through power. This hunt takes scientists and creators all across the globe to examine where this next source lies. One search took scientists at Lyxia, a SoCal Biotech Company, to Shenzhen China where they discovered a common yet super special substance: microalgae. Microalgae are unicellular photosynthetic microorganisms, living in saline or freshwater environments, that convert sunlight, water and carbon dioxide to algal biomass. This ability makes them a key energy source in all ecosystems and an even better source of nutrients. At Lyxia, they are attempting to use microalgae to reach their goal: producing natural specialty ingredients with sun, seawater, CO2 and microalgae. Their first focus has been producing “...the essential nutrient, eicosapentaenoic acid, more commonly known as the Omega-3 EPA… We [Lyxia] have now launched a series of products based on pure, natural, vegetarian EPA that is sustainably produced from microalgae..." </p><p>How absolutely tasty is that! </p><p>We virtually sat down with Lyxia’s Former R&D Senior Process Designer Peter Mponzi to find out more about it on the last episode of our first series, Alternative Careers in Biotech. </p><p>You can also learn more about Lyxia here: <a href="http://www.lyxia.com/">http://www.lyxia.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 19 Apr 2021 14:00:00 +0000</pubDate>
      <author>team@bc-la.org (Ananta Wadhwa, Dr. Yewande Pearse, Kathy Grotsch, Peter Mponzi, Damon Palermo, Daniel Graves)</author>
      <link>https://inside-biotech.simplecast.com/episodes/alternative-careers-in-biotech-peter-mponzi-former-rd-senior-process-designer-at-lyxia-jFq7FjO5</link>
      <content:encoded><![CDATA[<p>In Biotech, people are often on the hunt for more sustainable ways for humans to be energized in two major ways: through food and through power. This hunt takes scientists and creators all across the globe to examine where this next source lies. One search took scientists at Lyxia, a SoCal Biotech Company, to Shenzhen China where they discovered a common yet super special substance: microalgae. Microalgae are unicellular photosynthetic microorganisms, living in saline or freshwater environments, that convert sunlight, water and carbon dioxide to algal biomass. This ability makes them a key energy source in all ecosystems and an even better source of nutrients. At Lyxia, they are attempting to use microalgae to reach their goal: producing natural specialty ingredients with sun, seawater, CO2 and microalgae. Their first focus has been producing “...the essential nutrient, eicosapentaenoic acid, more commonly known as the Omega-3 EPA… We [Lyxia] have now launched a series of products based on pure, natural, vegetarian EPA that is sustainably produced from microalgae..." </p><p>How absolutely tasty is that! </p><p>We virtually sat down with Lyxia’s Former R&D Senior Process Designer Peter Mponzi to find out more about it on the last episode of our first series, Alternative Careers in Biotech. </p><p>You can also learn more about Lyxia here: <a href="http://www.lyxia.com/">http://www.lyxia.com</a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="39364587" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/46eb06bc-6d8f-4fee-834e-100849e91e96/audio/b88f8610-a654-4f9f-b303-02471ce63243/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Alternative Careers in Biotech: Peter Mponzi, Former R&amp;D Senior Process Designer at Lyxia</itunes:title>
      <itunes:author>Ananta Wadhwa, Dr. Yewande Pearse, Kathy Grotsch, Peter Mponzi, Damon Palermo, Daniel Graves</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/8a42d372-9082-4088-bf82-2f2b62630d86/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:41:00</itunes:duration>
      <itunes:summary> Blue-green, grown in freshwater and saltwater, and potentially the biggest new source of energy? It might sound too good to be true, but microalgae has all these possibilities and one more: it can be a food source! A vital energy source in all ecosystems, microalgae can be cultivated, dried, and manipulated to extract nutrients and compounds that can be used as nutritional supplements. One SoCal company, Lyxia, is taking advantage of this amazing substance by partnering with researchers in Shenzhen, China to extract a compound that is key for cardiovascular health. We sat down with Lyxia’s Former R&amp;D Senior Process Designer Peter Mponzi to find out more about it on the last episode of our first series, Alternative Careers in Biotech. </itunes:summary>
      <itunes:subtitle> Blue-green, grown in freshwater and saltwater, and potentially the biggest new source of energy? It might sound too good to be true, but microalgae has all these possibilities and one more: it can be a food source! A vital energy source in all ecosystems, microalgae can be cultivated, dried, and manipulated to extract nutrients and compounds that can be used as nutritional supplements. One SoCal company, Lyxia, is taking advantage of this amazing substance by partnering with researchers in Shenzhen, China to extract a compound that is key for cardiovascular health. We sat down with Lyxia’s Former R&amp;D Senior Process Designer Peter Mponzi to find out more about it on the last episode of our first series, Alternative Careers in Biotech. </itunes:subtitle>
      <itunes:keywords>careers, nutrition, biotech, industry, sustainability, science, socal, alternative, lyxia, microalgae</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>4</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">034bf450-a64a-4fcb-a112-346469e0c2b9</guid>
      <title>Alternative Careers in Biotech: Anna Skaya, Founder of Basepaws</title>
      <description><![CDATA[<p>Cats are humans’ other best friend! In Los Angeles alone, there are an estimated 771,076 households that have one or more cats as pets and unconditional sources of companionship and friendship. Despite the high number of cat owners in LA and all over the country, however, there is extremely little research about feline genetics when the numbers are compared to canine genetics and research. Meet Basepaws, a Los Angeles based startup, that is focusing to change this imbalance in research and bring feline research to the forefront. According to their website, “At the <a href="https://www.catdog2019.unibe.ch/program/#pane693504">Conference on Canine and Feline Genetics and Genomics (2019)</a>, for example, canine‑focused presentations outnumbered feline‑focused presentations roughly 5 to 1. In addition, when it comes to the number of sequenced genomes from each species, the goals (and available research funding) for the two fields look completely different."</p><p> Thus, to bridge this gap, their goal is to build the world’s largest feline genomics database. Learning genomic information about cats is extremely important because it enables us to better learn about caring about cats. Through DNA and a genomic library, we can learn more about diseases, health issues, and traits to create the best products for cats possible. We virtually sat down with Anna Skaya, the founder of Basepaws, to ask her all about it. You can also learn more by checking  out their website: <a href="https://basepaws.com/">https://basepaws.com</a>. </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 15 Mar 2021 21:43:01 +0000</pubDate>
      <author>team@bc-la.org (Daniel Graves, Kathy Grotsch, Damon Palermo, Anna Skaya, Ananta Wadhwa, Dr. Yewande Pearse)</author>
      <link>https://inside-biotech.simplecast.com/episodes/alternative-careers-in-biotech-anna-skaya-founder-of-basepaws-cPHgKg0C</link>
      <content:encoded><![CDATA[<p>Cats are humans’ other best friend! In Los Angeles alone, there are an estimated 771,076 households that have one or more cats as pets and unconditional sources of companionship and friendship. Despite the high number of cat owners in LA and all over the country, however, there is extremely little research about feline genetics when the numbers are compared to canine genetics and research. Meet Basepaws, a Los Angeles based startup, that is focusing to change this imbalance in research and bring feline research to the forefront. According to their website, “At the <a href="https://www.catdog2019.unibe.ch/program/#pane693504">Conference on Canine and Feline Genetics and Genomics (2019)</a>, for example, canine‑focused presentations outnumbered feline‑focused presentations roughly 5 to 1. In addition, when it comes to the number of sequenced genomes from each species, the goals (and available research funding) for the two fields look completely different."</p><p> Thus, to bridge this gap, their goal is to build the world’s largest feline genomics database. Learning genomic information about cats is extremely important because it enables us to better learn about caring about cats. Through DNA and a genomic library, we can learn more about diseases, health issues, and traits to create the best products for cats possible. We virtually sat down with Anna Skaya, the founder of Basepaws, to ask her all about it. You can also learn more by checking  out their website: <a href="https://basepaws.com/">https://basepaws.com</a>. </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="35564931" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/03646f78-dd51-40e5-ac37-99040a87c416/audio/4908384e-6bdc-47dc-ba88-6e908f779b26/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Alternative Careers in Biotech: Anna Skaya, Founder of Basepaws</itunes:title>
      <itunes:author>Daniel Graves, Kathy Grotsch, Damon Palermo, Anna Skaya, Ananta Wadhwa, Dr. Yewande Pearse</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/6b5961e1-d78b-4540-8627-d2cadd97c255/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:37:03</itunes:duration>
      <itunes:summary>Drawn by the pitter patter of their little paws, the sweet purrs, and the source of unconditional companionship and friendship, cats or felis cactus have been interacting with and companions of humans for the last 8,000 years. Despite our long history with cats, however, little is known about their health and ideal lifestyle, especially when compared to dogs. One LA-based startup, however, is attempting to change this gap: Basepaws. Basepaws works to create a genomic database that enables the company to learn more about cat breeds, traits, and their health. This goal is built on the idea that understanding cats genetically will enable us to better serve cats and improve their lives. 

Interested in learning how exactly they do it? We virtually sat down with Basepaw’s founder, Anna Skaya, to find out more about Basepaws. Join Dr. Yewande Pearse, PhD on our 3rd episode of ‘Inside Biotech’ to find out more. </itunes:summary>
      <itunes:subtitle>Drawn by the pitter patter of their little paws, the sweet purrs, and the source of unconditional companionship and friendship, cats or felis cactus have been interacting with and companions of humans for the last 8,000 years. Despite our long history with cats, however, little is known about their health and ideal lifestyle, especially when compared to dogs. One LA-based startup, however, is attempting to change this gap: Basepaws. Basepaws works to create a genomic database that enables the company to learn more about cat breeds, traits, and their health. This goal is built on the idea that understanding cats genetically will enable us to better serve cats and improve their lives. 

Interested in learning how exactly they do it? We virtually sat down with Basepaw’s founder, Anna Skaya, to find out more about Basepaws. Join Dr. Yewande Pearse, PhD on our 3rd episode of ‘Inside Biotech’ to find out more. </itunes:subtitle>
      <itunes:keywords>careers, biotech, science, alternative, cats, basepaws, genetics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>3</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">6d976cf7-a6a7-42d4-ae94-7b440e602010</guid>
      <title>Alternative Careers in Biotech: Nadja Ortelt and Allan Lasser, Founders of Massive Science</title>
      <description><![CDATA[<p>We use science everyday, scientists are discovering something new everyday, and a piece of scientific news might just change the world everyday! Especially in the 21st century, keeping up with the world of science is imperative. Getting the most accurate, most digestible, and most relevant scientific news, however, can be quite challenging as misinformation rampant, and scientific news can be full of a lot of information that is inaccessible to the public. So, how do we enable and create more accessible, exciting, and engaging science media online that people can learn from and share with their friends and families? How do people know they can trust the news, fact check, and work to better understand new scientific discoveries? </p><p> These questions are where, Massive Science, a scientific content and media company, comes in. Powered by a “Massive Science Consortium” which is a group of scientific experts from over 50 countries, in over 150 fields, and at over 700 institutions, Massive Science aims to create a space where experts can share cutting edge scientific news and research via their accessible online platform by training scientists on how to be powerful scientific storytellers. Massive Science teaches the members of the Consortium how to create a more engaging narrative regarding their discoveries  by empowering  them to work with a professional team of editors and other researchers. </p><p>Are you interested in learning more about how Massive Science does it? Join Dr. Yewande Pearse, PhD in BCLA’s 2nd episode of Alternative Careers in Biotech as she chats with the two founders of Massive Science, Nadja Ortelt and Allan Lasser!</p><p>To learn more about Massive Science, check out: <br /><a href="https://massivesci.com/">https://massivesci.com</a>  </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Mon, 15 Feb 2021 16:46:32 +0000</pubDate>
      <author>team@bc-la.org (Allan Lasser, Ananta Wadhwa, Daniel Graves, Dr. Yewande Pearse, Kathy Grotsch, Nadja Ortelt, Damon Palermo)</author>
      <link>https://inside-biotech.simplecast.com/episodes/alternative-careers-in-biotech-nadja-ortelt-and-allan-lasser-founders-of-massive-science-1JQVy2Kt</link>
      <content:encoded><![CDATA[<p>We use science everyday, scientists are discovering something new everyday, and a piece of scientific news might just change the world everyday! Especially in the 21st century, keeping up with the world of science is imperative. Getting the most accurate, most digestible, and most relevant scientific news, however, can be quite challenging as misinformation rampant, and scientific news can be full of a lot of information that is inaccessible to the public. So, how do we enable and create more accessible, exciting, and engaging science media online that people can learn from and share with their friends and families? How do people know they can trust the news, fact check, and work to better understand new scientific discoveries? </p><p> These questions are where, Massive Science, a scientific content and media company, comes in. Powered by a “Massive Science Consortium” which is a group of scientific experts from over 50 countries, in over 150 fields, and at over 700 institutions, Massive Science aims to create a space where experts can share cutting edge scientific news and research via their accessible online platform by training scientists on how to be powerful scientific storytellers. Massive Science teaches the members of the Consortium how to create a more engaging narrative regarding their discoveries  by empowering  them to work with a professional team of editors and other researchers. </p><p>Are you interested in learning more about how Massive Science does it? Join Dr. Yewande Pearse, PhD in BCLA’s 2nd episode of Alternative Careers in Biotech as she chats with the two founders of Massive Science, Nadja Ortelt and Allan Lasser!</p><p>To learn more about Massive Science, check out: <br /><a href="https://massivesci.com/">https://massivesci.com</a>  </p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="36194055" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/427184e7-98cc-4219-b2e3-c201fc6db6ac/audio/6e90f17e-8c4d-413f-87ff-429142ad2a25/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Alternative Careers in Biotech: Nadja Ortelt and Allan Lasser, Founders of Massive Science</itunes:title>
      <itunes:author>Allan Lasser, Ananta Wadhwa, Daniel Graves, Dr. Yewande Pearse, Kathy Grotsch, Nadja Ortelt, Damon Palermo</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/6a6aa510-3d4d-4d89-9056-36d51ce0a0a7/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:37:43</itunes:duration>
      <itunes:summary>The bottom line is science news is important. Being well-versed in scientific findings enables a person to keep up with the latest issues and the newest riveting discoveries, making topics like COVID-19 less daunting. Science news, however, is often hard to read or full of misinformation. 

Enter Massive Science: a unique scientific content and media company which is working to address these issues. Interested in learning how Massive Science is helping make science news more exciting and accessible? 

To find out, join Dr. Yewande Pearse, PhD in BCLA’s 2nd episode of Alternative Careers in Biotech as she chats with the founders of Massive Science, Nadja Ortelt and Allan Lasser! 
</itunes:summary>
      <itunes:subtitle>The bottom line is science news is important. Being well-versed in scientific findings enables a person to keep up with the latest issues and the newest riveting discoveries, making topics like COVID-19 less daunting. Science news, however, is often hard to read or full of misinformation. 

Enter Massive Science: a unique scientific content and media company which is working to address these issues. Interested in learning how Massive Science is helping make science news more exciting and accessible? 

To find out, join Dr. Yewande Pearse, PhD in BCLA’s 2nd episode of Alternative Careers in Biotech as she chats with the founders of Massive Science, Nadja Ortelt and Allan Lasser! 
</itunes:subtitle>
      <itunes:keywords>careers, massive, biotech, science, alternative, news</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>2</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2bcec82a-a171-4665-91ef-f47115670ce2</guid>
      <title>Alternative Careers in Biotech: Kayleen Sabino, VP of Operations at Cannalysis</title>
      <description><![CDATA[<p> A booming industry around the United States, the Cannabis industry’s worth in this country could be greater than the GDP of 9 US States. In Southern California, Cannabis is even more important and commonly used than the rest of the country with the percent increase of usage in Los Angeles (LA) skyrocketing to 62% from March 2018 to March 2019. From edibles to lotions, Cannabis can be found in many forms making the industry even more interdisciplinary and varied than ever before. With the great usage of this drug and substance that was once considered dangerous, however, comes the need for government regulations, stringent product testing, and other mechanisms to keep consumers safe. </p><p>The need to make sure products meet a certain standard brings us to Cannalysis, a company based in Los Angeles that focuses on efficiently testing new cannabis products so that they meet state guidelines. As quoted from their website, Cannalysis is “... inventing the best way to test them [Cannabis Products]” by employing robotics for “less error with groundbreaking express sample prep automation” throughout the testing process. Creating a streamlined testing process is key, and Cannalysis is at the forefront. </p><p>Are you interested in learning more about how this Los Angeles staple goes from the plant to your pocket safely? Join Dr. Yewande Pearse PhD, Social Media Associate at Biotech Connection Los Angeles, as she speaks with Kayleen (Leong) Sabino, Vice President of Operations at Cannalysis. Sabino virtually <i>sat down</i> to discuss the science being Cannalysis’ amazing work and what the future of the cannabis industry in LA might look like moving forward. </p><p>For more info on Cannalysis see the following links:<br /><a href="https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/1" target="_blank">https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/1</a><br /><a href="https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/4" target="_blank">https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/4 </a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></description>
      <pubDate>Fri, 15 Jan 2021 21:00:00 +0000</pubDate>
      <author>team@bc-la.org (Kayleen Sabino, Dr. Yewande Pearse, Kathy Grotsch, Ananta Wadhwa)</author>
      <link>https://inside-biotech.simplecast.com/episodes/alternative-careers-in-biotech-kalyeen-sabino-vp-of-operations-at-cannalysis-CnXkwEua</link>
      <content:encoded><![CDATA[<p> A booming industry around the United States, the Cannabis industry’s worth in this country could be greater than the GDP of 9 US States. In Southern California, Cannabis is even more important and commonly used than the rest of the country with the percent increase of usage in Los Angeles (LA) skyrocketing to 62% from March 2018 to March 2019. From edibles to lotions, Cannabis can be found in many forms making the industry even more interdisciplinary and varied than ever before. With the great usage of this drug and substance that was once considered dangerous, however, comes the need for government regulations, stringent product testing, and other mechanisms to keep consumers safe. </p><p>The need to make sure products meet a certain standard brings us to Cannalysis, a company based in Los Angeles that focuses on efficiently testing new cannabis products so that they meet state guidelines. As quoted from their website, Cannalysis is “... inventing the best way to test them [Cannabis Products]” by employing robotics for “less error with groundbreaking express sample prep automation” throughout the testing process. Creating a streamlined testing process is key, and Cannalysis is at the forefront. </p><p>Are you interested in learning more about how this Los Angeles staple goes from the plant to your pocket safely? Join Dr. Yewande Pearse PhD, Social Media Associate at Biotech Connection Los Angeles, as she speaks with Kayleen (Leong) Sabino, Vice President of Operations at Cannalysis. Sabino virtually <i>sat down</i> to discuss the science being Cannalysis’ amazing work and what the future of the cannabis industry in LA might look like moving forward. </p><p>For more info on Cannalysis see the following links:<br /><a href="https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/1" target="_blank">https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/1</a><br /><a href="https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/4" target="_blank">https://www.thesocialclub.tv/shows/xyz-news/season/2/episode/4 </a></p>
<p><p>Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!</p><p>To learn more about BCLA’s events and consulting visit <a href="https://www.bc-la.org/">our website</a>.</p><p>Follow BCLA on <a href="https://www.linkedin.com/in/bclosangeles/">LinkedIn</a></p><p>&nbsp;</p></p>]]></content:encoded>
      <enclosure length="34291017" type="audio/mpeg" url="https://cdn.simplecast.com/audio/dd0726ca-e626-46dd-bc58-9afbc1c1f3a4/episodes/5fde0f8f-a80e-480e-94fb-17c9412f2785/audio/3bfa8820-056f-4045-abc0-be560511e54f/default_tc.mp3?aid=rss_feed&amp;feed=_70AInrh"/>
      <itunes:title>Alternative Careers in Biotech: Kayleen Sabino, VP of Operations at Cannalysis</itunes:title>
      <itunes:author>Kayleen Sabino, Dr. Yewande Pearse, Kathy Grotsch, Ananta Wadhwa</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/548a9d15-eb33-4a8c-92d2-a3172592b55c/faed0cb9-6b79-446f-b6bd-21f699409da1/3000x3000/insidebiotech-artwork.jpg?aid=rss_feed"/>
      <itunes:duration>00:35:43</itunes:duration>
      <itunes:summary>Cannabis use has skyrocketed in Los Angeles (LA). From March 2018 to March 2019, the percent increase of the use of this substance in LA was a whopping 62%. 

Interested in learning more about how this Los Angeles staple goes from the plant to your pocket safely? Join Dr. Yewande Pearse PhD, Social Media Associate at Biotech Connection Los Angeles, as she speaks with Kayleen (Leong) Sabino, Vice President of Operations at Cannalysis - an LA based company that focuses on efficiently testing new cannabis products so that they meet state guidelines. Sabino virtually sat down to discuss how Cannalysis does it and what the future of the cannabis industry in LA might look like moving forward. </itunes:summary>
      <itunes:subtitle>Cannabis use has skyrocketed in Los Angeles (LA). From March 2018 to March 2019, the percent increase of the use of this substance in LA was a whopping 62%. 

Interested in learning more about how this Los Angeles staple goes from the plant to your pocket safely? Join Dr. Yewande Pearse PhD, Social Media Associate at Biotech Connection Los Angeles, as she speaks with Kayleen (Leong) Sabino, Vice President of Operations at Cannalysis - an LA based company that focuses on efficiently testing new cannabis products so that they meet state guidelines. Sabino virtually sat down to discuss how Cannalysis does it and what the future of the cannabis industry in LA might look like moving forward. </itunes:subtitle>
      <itunes:keywords>careers, biotech, testing, cannabis, industry, weed, alternative, cannalysis</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>1</itunes:episode>
    </item>
  </channel>
</rss>